Process for the preparation of antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and of their corresponding sulfoxides and sulfones
20 claims: 1 independent, 19 dependent
- 1KEIVIRDIOAgte I a . - Processo para a preparação de um composto da fórmula S(0) n - Rl na qual R 1 = alquilo em Cq-C^, monofluoroalquilo ou polifluoroal· quilo em Cq-C^ ou alilo;Rg e Ry independentemente, = 2-tienilo, 3-piridilo, 3-pi· ridilo-N-óxido, o u Yq = alquilo em Cq-G^ alcóxi em Cq-C^, E, Cl, Br, H, (Rtj) 2 R ou em que R^ = metilo ou etilo e m = 0, 1 ou 2;Y 2 = Η, P ou Cl;= H ou alquilo em C-j-C^;Rg = H, alquilo em C^C^, alilo, -CH 2 CH 2 ll(Ry) 2 , -OHORg,
- 22-tetrahidropiranilo, 2-tetrahidrofuranilo, 0 Y, ,1 -CR 10’ X II i R c -SO, -CR(R2j_) 2 » alquilsulfonilo em C^-C^ ou -COR^;Ry = H, metilo ou etilo;Rg = H ou metilo;θ II Rg = alquilo em C^-C^, benzilo, -CELjCH^OCH^ ou -GRj_q} R lo = alquilo em C^-C^ ou benzilo;R-^ = metilo ou etilo;. X = 0 ou S;Y 3 = Η, P, Cl, Br, alquilo em C^-C^, alcoxi em C^-C^ ou nitro;n = 0, 1 ou 2;com a condição de que quando os símbolos R 2 e R^ significam em que Yj_ e Y 2 são ambos iguais a H, ambos Rj. é CP^;e ainda com a condição de que, quando R^ = CHy R 2 em que um dos símbolos Y^ e Y 2 significa P e o outro significa H, R^ = H e Rg = Η, n não pode ser 2;ou dos seus sais de -adição de ácido farmaeêuticamente adequados em que pelo menos, um dos símbolos R 2 ou R = 3-piridilo, Yj_ = (Rg) 2 N ou Rg = -CH 2 CH 2 R(R 7 ) 2 , caracterizado pelo facto de a) se fazer contactar um composto da fórmula r /a.50 na qual R 2 , R^ e R^ são como anteriormente definidos, com um cloreto de sulfenilo, R^SCl, em que R^ é como anteriormente definido, e opcionalmente, b) se fazer contactar 0 produto da fase (a) oom um agente oxidante adequado;c) opcionalmente se alquilar, acilar ou sulfonar 0 produto de (a) ou (b), e d) opcionalmente se transformar 0 produto de (a), (b) ou (c) num sal farmaceuticamente adequado. 25. - Processo para a preparação de um composto de acordo com a reivindicação 1, caracterizado pelo facto dei a) se fazer contactar um composto da fórmula na qual R 2 , R3 e R^ são como anteriormente definidos, com um halogeneto de alquilo, R^X, em que R^ ó como anteriormente definido ou com uma olefina fluorada, na presença de ums base orgânica adequada e, opcionalmente, b) se fazer contactar 0 produto da fase (a) com um agente oxidante adequado;c) opcionalmente se alquilar, acilar ou sulfonar o produto de (a) ou (b), e d) opcionalmente se transformar o produto de (a), (b) ou (c) num sal farmaceuticamente adequado.
- 33 S . - Processo de acordo com a reivindicação 1, ca racterizado pelo facto de R^ = metilo ou trifluorometilo.
- 44§. - Processo de acordo com a reivindicação 3, caracterizado pelo facto de R-^ = metilo e n = 2.
- 55 ã . - Processo de acordo...com a reivindicação 3, caracterizado pelo facto de R^ = trifluorometilo e n = 2.
- 66®. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de R 2 e R^, independentemente, serem l 2 .
- 77a. _ p r ocesso de acordo com a reivindicação 6, caracterizado pelo facto de Y^ = P, ou me^óxi.
- 88®. - Processo de acordo oom a reivindioação 7, caracterizado pelo facto de = P. 95. - Processo de acordo com a reivindicação 6, caracterizado pelo facto de Y 2 = H. 105. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de R 2 = 3-piridilo. 113. - processo de acordo com a reivindicação 1, caracterizado pelo facto de Rg = H. 125. - Processo de acordo com'a reivindicação 1, caracterizado pelo faoto de n = 0 ou 2. 135. - Processo de acordo oom a reivindicação 12, caracterizado pelo facto de n = 2. 14 a . - Processo de acordo com a reivindicação 6, caracterizado pelo facto de = metilo ou trifluorometilo;R^ = H;Rg = Η;n = 0 ou 2;Y^ = P, Cl ou metóxi, e Yg = H. 15 a . - Processo de acordo com a reivindicação 14, caracterizado pelo facto de Y^ = P. 16 . - Processo de acordo oom a reivindicação 14, caracterizado pelo facto de n = 2. 17 a · - Processo de acordo com a reivindicação 1, caracterizado pelo facto de R^ = H. 18a. - Processo de acordo com a reivindicação 11, caracterizado pelo facto de R 2 e R^, independentemente, serem 19 â . - Processo de acordo oom a reivindicação 11 caracterizado pelo facto de R 2 = 3-piridilo, 203. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de R^ = CP^;R 2 e R^ serem ambos 21$. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de R^ = CP^} R 2 = 3-piridilo;R^ = ! R4 — Hj Rg = H, e n = 0. 223. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 1, de preferência, numa proporção de cerca de 0,5 a 95 em peso, de substância activa. 23®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto de acordo com a reivindicação 3, de preferência numa proporção de cerca de 0,5 a 95 %, em peso, de substância activa. 24®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 4, de preferência, numa proporção de cerca de 0,5 a 95 em peso, de substância activa.. 25®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uraa quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 5, de preferência, numa proporção de cerca de 0,5 a 95 em peso, de substância activa. 26®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 6, de preferência, numa proporção de cerca de 0,5 a 95 em peso, de substância activa. 27®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um··, veí culo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 7, de preferência, numa proporção de 0,5 a 95 em peso, de substância activa. 28®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 8, de preferência numa proporção de 0,5 a 95 em peso, de substância activa. 29 a . - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 99, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 30 a . - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1010, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 31 a . - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1111, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 32 a . - Processo para a jxqparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veí culo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1212, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 33 a . - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1313, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 34 a - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequada e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1414, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 355. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1515, de preferência, numa proporção de 0,5 a 95$, em peso, de substância activa. 365. _ Processo para a preparação de composições, farmacêuticas, cracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1616, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 37 s . - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1717, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 38S. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamátória eficaz de um composto preparado de acordo com a reivindicação
- 1818, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. 39 3 · - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 1919, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa, 405. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação
- 2020, de preferência, numa proporção de 0,5 a 95 $, em peso, de substância activa. .... - ’ 41®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 21, de preferência, numa proporção de 0,5 a 95 em peso, de substância activa. 42®. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 1, de preferência, numa dose diána compreendida entre 0,2 e 10 mg de substância activa por kg e por-*dia, administrada 2 a 4 vezes por dia. 43®. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 3, de preferência, numa dose diária compreendida entre 0,2 e 1) mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 44 a - - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 4, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 45®. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 5, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 46®. - Processo para conseguir um efeito terapêu tico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 6, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 47a. - Processo para conseguir um efeitò terapêá tico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 7, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg ’.e por dia, administrada 2 a 4 vezes por dia. 485. _ Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrí tica contendo um composto preparado de acordo com a reivindicação 8, de preferência numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 493. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 9, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 50®. _ Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítiea contendo um composto preparado'de acord.o com a reivindicação 10, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 515. _ Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 11, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 52S. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 12, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 53 a . - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido' mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 13, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 54 s . - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo faoto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 14, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 55 â . - Processo para conseguir um efeito terapêutico da artrite numa mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 15, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 5ôs. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindica ção IS, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 57 a . - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítioa contendo um composto preparado de acordo com a reivindicação 17, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 58§. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 18, de preferência numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 59 a - - Processo para conseguir um efeito terapêutico da artrite num-mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 19, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 605. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 20, de preferência numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 6is. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 21, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 625. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de R^ e R-,, independentemente, serem em que Y^ = alquilo em C^-C^, alcoxi em Cj-C^, F, 01, Br, H ou (r 5 ) 2 n ;Y 2 = Η, P ou Ol;R4 = H ou alquilo em Cj-C^;e 63 a . - Processo de acordo com a reivindicação R. R, = C 6 H 5 ;H;R, Rg = H;e n = 0. 64 â . - Processo de acordo com a reivindicação 1, caracterizado pelo facto de R^ = 0P 3 ;r 4 = σι·ι 3 ;Rg = H;.e n = 0. R^ e Rp ambos = Jf F;65 3 · - Processo de acordo com a reivindicação 1, caracterizado pelo facto de Rj. - 0F 3 ;Rg = 3-piridilo;R 4 = H;Rg = H;e n = 0. 66 a , _ Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 62, âe preferência, numa proporção de 0,5 a 95 %, em peso, de substância activa. 67®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 63, de preferência, numa proporção de 0,5 a 95 em peso, de substância activa. 68®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 64, de preferência, numa proporção de 0,5 a 95 em peso, de substância activa. 69®. - Processo para a preparação de composições farmacêuticas, caracterizado pelo facto de se misturar um veículo farmacêutico adequado e uma quantidade anti-inflamatória eficaz de um composto preparado de acordo com a reivindicação 65, de preferência, numa proporção de 0,5 a 95 em peso, de substância activa. 70®. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 62, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 71®. - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 63, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 72®. - Processo para conseguir um efeito tera1 ·» » tpêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítlca contendo um composto preparado de acordo com a reivindicação 64, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia. 73 a . - Processo para conseguir um efeito terapêutico da artrite num mamífero, caracterizado pelo facto de se administrar ao referido mamífero uma composição anti-artrítica contendo um composto preparado de acordo com a reivindicação 65, de preferência, numa dose diária compreendida entre 0,2 e 10 mg de substância activa por kg e por dia, administrada 2 a 4 vezes por dia.
Independent claims20
1,507 paragraphs in 157 sections, as filed
The present invention relates to anti-inflammatory pyrroles.
J. Szmuskovicz et al. J. Med. Chem., 9 (4), 527-
-36 (1966) describes the synthesis and biological activity of a clinically tested anti-inflammatory agent.
<img file="PT72087B_D0001.tif" />
<img file="PT72087B_D0002.tif" />
Yoshida et al., US Patent 3709906 discloses 2-alkyl-4,5-diphenylpyrrole derivatives which are useful as anti-inflammatory agents.
There is a continuing need for safe and efficient anti-inflammatory agents. Inflammation is a disease process characterized by redness, fever, swelling and pain. Arthritis, in its various forms, is the most prevalent, chronic and severe of inflammatory diseases, traumatic injury and infection also involving inflammation, and anti-inflammatory drugs are often used in its treatment. The effectiveness of most commercial anti-inflammatory agents is limited due to toxicity and adverse side effects. Many of them produce gastric irritation and other effects such as changes in blood cells and the central nervous system. Adrenocortical steroids produce gastric irritation and suppression of normal adrenal function.
In addition to anti-inflammatory properties, compounds within the scope of the present invention demonstrate analgesic activity in the assay process. This additional property is desirable in the treatment of arthritis or related diseases; however, compounds exhibiting this property may be employed alone to relieve pain.
Summary of the Invention
The present invention relates to compounds of formula I, pharmaceutical compositions containing them and processes for using these compounds to treat arthritis or alleviate odorants in mammals:
<img file="PT72087B_D0003.tif" />
<img file="PT72087B_D0004.tif" />
L · · in which
Rj. = C 1 -C 4 alkyl, monofluoroalkyl or C 1 -C 4 polyfluoroalkyl or allyl;
R<sub>2</sub> and Rj independently = 2-thienyl, 3-pyridyl,
3-pyridyl N-oxide
<img file="PT72087B_D0005.tif" />
or
Y4 = alkyl in alkoxy in O4 -O4,
F, Cl, Br, H (R<sub>5</sub>)<sub>2</sub>N or R<sub>5</sub>(0)<sub>m</sub> wherein Rej = methyl or ethyl at = 0, 1 or 2;
Y<sub>2</sub> = H, F or Cl;
= 30 to C1 -C6 alkyl;
Rg = H, alkyl at 0<sub>1</sub>-Ç<sub>4></sub> allyl -CH<sub>2</sub>CH<sub>2</sub>N (R<sub>7</sub>)<sub>2</sub>,
CH0R<sub>what</sub>, 2-tetrahydropyranyl »8 <sup>y</sup>
R
<img file="PT72087B_D0006.tif" />
it / Y
Rr
X
II
-CN (Rj4)<sub>2</sub> alkylsulfonyl in or -CORjq;
= H, methyl or ethyl;
Rg = H or methyl;
Rg = C1 -C10 alkyl benzyl, -CH3 Cl2<sup>00</sup>^> or 0
-CR<sub>10</sub>,
R<sub>lo</sub> = C1 -C4 alkyl or benzyl;
<sup>R</sup>11 <sup>= or</sup> θ ^ ϋο;
X = 0 or S;
Y<sub>3</sub> = H, F, Cl, Br, C1 -C4 alkyl, C1 -C4 alkoxy or nitro; n = 0, 1 or 2;
<img file="PT72087B_D0007.tif" />
on what
Y<sub>±</sub> and Y<sub>2</sub> are both equal to H, is CF3;
Rt = CH<sub>3</sub>, R<sub>2</sub> =
<img file="PT72087B_D0008.tif" />
<img file="PT72087B_D0009.tif" />
where in one of the symbols Y ^ and Y<sub>2</sub> = F and the Other is
H, R<sub>4</sub> = 4 and Rg = H, n cannot be equal to 2, or their pharmaceutically appropriate acid addition salts where at least one of the symbols R<sub>2</sub> or R<sub>3</sub> '3-pyridyl, <sup>Y</sup>1 <sup>=</sup> ^2<sup>N</sup>’ <sup>or</sup>
Rg = -CH<sub>2</sub>CH<sub>2</sub>N (R<sub>7</sub>)<sub>2</sub>.
Detailed Description of the Invention
Preferred Compounds
Preferred compounds for their degree of activity, safety and / or ease of synthesis include those wherein, independently:
<img file="PT72087B_D0010.tif" />
a) Rj = methyl or trifluoromethyl; or
<img file="PT72087B_D0011.tif" />
and preferably Yj = F, Cl, methoxy and more preferably F; Y<sub>2</sub> = H; or
e) Rg = 3-pyridyl; or
f) R<sub>4</sub> = H; or
g) Rg = H; or
h.) n = O or 2 and more preferably n = 2 *
Compounds of a preferred scope include those wherein;
<img file="PT72087B_D0012.tif" />
methoxy and more preferably F; Y<sub>2</sub> = H; R<sub>4</sub> = H;
Rg = H; en = 0 or 2 and more preferably n = 2.
Examples of preferred compounds for their activity are those in which
<img file="PT72087B_D0013.tif" />
n = 0, 1 or 2.
Other examples of preferred compounds are those wherein
A) R<sub>x</sub> = CFg;
r<sub>2</sub> = 3-pyridyl;
Rg = CgHg;
R<sub>4</sub> = Η; R<sub>6</sub> = Η; n = 0.
<img file="PT72087B_D0014.tif" />
R<sub>3</sub> = CgH<sub>5</sub>JK<sub>4</sub> = H;
Rg = H; en = 0.
<img file="PT72087B_D0015.tif" />
D) R<sub>x</sub> = 0F<sub>3</sub>;
R<sub>2</sub> = 3-pyridyl;
Laughs
R<sub>4</sub> = H;
Rg = H, · en = 0.
<img file="PT72087B_D0016.tif" />
Synthesis
The compounds of the present invention may be prepared from 2,3-diarylpyrroles. A process for preparing 2,3-diarylpyrroles involves the reaction of acetylene diesters (X-aminodeoxybenzoins), followed by hydrolysis and decarboxylation according to the procedure employed by J. Szmusskovicz et al., J. Med. Ohem. , 527 (1966) and U.S. Patent No. 3,462,451 for the synthesis of 2,3-bis (4-methoxyphenyl) pyrrole (Scheme 1).
<img file="PT72087B_D0017.tif" />
{;
Scheme I
<img file="PT72087B_D0018.tif" />
<img file="PT72087B_D0019.tif" />
Another process for the preparation of 2,3-diarylpyrroles is a modification of a process T. Severin and H. Poehlmann, Chem. Ber., 110, 491 (1977), which describes the preparation of monoaryl pyrroles. Using substituted deoxybenzoines, the desired 2,3-diarylpyrroles yield (Scheme II).
.1 ·· '
Scheme II
HCCH + NH<sub>?</sub>N (CH,) £ ->
II «1
Arch<sub>2 </sub>Ar 4 = 0
NaOEt
H0 = 0
AtC = CH-CH = NN (CH<sub>3</sub>) <sub>g</sub>
Ar'C = 0
HC = M (CH<sub>3</sub>)<sub>2</sub> ^<sup>The</sup>2^2<sup>G</sup>4 • K ,,
<img file="PT72087B_D0020.tif" />
<img file="PT72087B_D0021.tif" />
The preparation of 4,5-diaryl-3-alkylpyrroles may be carried out by various processes. Firstly, esters of
4,5-diarylpyrrole-3-cartioxylate prepared by, for example, the process of AM van leusen et al., Tet. Letters, 5337 (1972) may be reduced to 4,5-diaryl-3-methylpyrroles by lithium aluminum hydride / following the general procedure of R. 1. Hinman and S. Theodoropulos, J. Org. Chem., 28, 3052 (1963/7.
<img file="PT72087B_D0022.tif" />
Secondly, 4,5-diaryl-3-propylpyrroles can be prepared by Olaisen rearrangement of the 2-allyl-thiopyrroles thio group, followed by Raney nickel reduction / general procedure by K. Teo et al., Can. J. Chem. 56, 221 (1978/7.
<img file="PT72087B_D0023.tif" />
ACGO quinoline
<img file="PT72087B_D0024.tif" />
Thirdly, 4,5-diaryl-3-alkylpyrroles may be prepared by the general process of N. Engel and W. Steglihh,
Angew. Chem, Int, Ed, Engl., 17, 676 (1978), from N-allylcarboxamides,
<img file="PT72087B_D0025.tif" />
<img file="PT72087B_D0026.tif" />
<img file="PT72087B_D0027.tif" />
<img file="PT72087B_D0028.tif" />
? '·?
The introduction of an alkylthio functionality is accomplished in several ways. Firstly, trifluoromethanesulfenyl chloride reacts directly and almost quantitatively with diarylpyrroles to give the substituted 2-trifluoromethylthio compounds.
<img file="PT72087B_D0029.tif" />
CI ^ SCl
At<sub>2</sub>CO<sub>3</sub> ether
<img file="PT72087B_D0030.tif" />
<img file="PT72087B_D0031.tif" />
Secondly, other alkylthio pyrroles may also be prepared directly by reacting an alkanesulfenyl chloride (such as methanesulfenyl chloride) with a 2,3-diarylpyrrole in an inert organic solvent such as tetrahydrofuran, diethyl ether or dioxane at -8020 to 2520.
Air
<img file="PT72087B_D0032.tif" />
R,
RjSCl <sup>At</sup>2<sup>G0</sup>3 ether
<img file="PT72087B_D0033.tif" />
<img file="PT72087B_D0034.tif" />
Third, the introduction of other groups
<img file="PT72087B_D0035.tif" />
Alkylthio is also performed in a two-step process involving substitution by cupric thiocyanate, thiocyanogen or the like to obtain the 2-thiocyanate derivative, and then hydrolysis in the presence of an alkyl halide, for example methyl iodide, or fluorinated olefin. for example tetrafluoroethylene.
<img file="PT72087B_D0036.tif" />
Fourth, trifluoromethanesulfenyl chloride reacts with 4,5-diarylpyrrole-2-carboxaldehydes and 4,5-diarylpyrrole-2-carboxylic acids to give 4,5-diaryl-2- (trifluoromethylthio) pyrroles directly (with concomitant loss). carbon monoxide and carbon dioxide, respectively).
<img file="PT72087B_D0037.tif" />
<img file="PT72087B_D0038.tif" />
Oxidation of 2-alkylthio compounds with suitable oxidizing agents such as m-chloroperoxybenzoic acid (mClPBA) gives the corresponding sulfoxides and sulfones.
<img file="PT72087B_D0039.tif" />
The non-hydrogen substituent R 6 of Formula I may be introduced by direct alkylation, acylation or sulfonylation of the compounds of Formula I wherein R = H. Esss,
The reaction may be carried out in the absence or presence of a base such as potassium carbonate, pyridine, triethylamine, potassium t-butoxide, methyl lithium, dimethyl sodium or the like. The reaction may be carried out in a homogeneous phase using the reagent as a solvent or in the presence of an inert solvent including but not limited to dimethylformamide, glime, THF, pyridine and methylene chloride. The reaction temperature may range from -78 ° C to<sup>9</sup>C to boiling point of solvent or reagents if excess is used as solvent. Examples of alkylating, acylating and sulfonylating agents which may be employed are allyl halides; alkyl halide such as methyl iodide; dimethylaminoethyl chloride; alkoxymethyl halides, such as benzyloxymethyl chloride; acyloxymethyl halides such as chloromethylpivalate; dihydropyran; ethyl vinyl ether; 2-chlorotetrahydrofuran; alkyl chloroformates such as ethyl chloroformate; dialkylcarbamoyl chlorides, such as diethylcarbamoyl chloride; dialkylthiocarbamoyl chlorides, such as diethylthiocarbamoyl chloride; alkanoic anhydrides and alkanoyl halides, such as acetic anhydride; aroyl halides such as benzoyl chloride; alkanesulfonyl halides such as methanesulfonyl chloride; arylsulfonyl halides such as benzenesulfonyl chloride.
The preparation of pharmaceutically suitable salts
<img file="PT72087B_D0040.tif" />
of compounds of Formula I should be made according to well known salt formation techniques.
The preparation of these compounds is further illustrated by the following examples. All parts are by weight and temperatures are expressed in degrees Centigrade unless otherwise specified.
Preparation 1
2,3-Diphenylpyrrole (Process A)
A. 4<sub>></sub>5-Pinylpyrrole-2<sub>></sub>Dimethyl 3-dioarboxylate
In a 2 liter 3-neck RB vial with mechanical stirrer and condenser were placed 76.7 g (0.31 mole desylamine hydrochloride / Psehorr et al., Chem. Ber. 35, 2740 (1902-7, 750 ml). methanol, 88 g (0.62 mole) (freshly distilled) dimethyl acetylenedicarboxylate and 61 g (0.75 mole) anhydrous sodium acetate The mixture was heated at reflux for 2 hours. Then an additional 44 g (0.31 mole) of dimethyl acetylenedicarboxylate was added and heated continuously for a further two hours. While the reaction mixture was still heated to reflux, concentrated hydrochloric acid (~ 60 mL to pHn / 2) was added dropwise. The mixture was heated at reflux for a further 1 hour and then poured into 2 liters of water containing 200 ml of 10% sodium bicarbonate solution. With stirring, more sodium bicarbonate was added until the solution became neutral. The precipitated gummy solid was collected and washed with water. Trituration of this gummy material with <v500 ml of 50% aqueous ethanol gave a brown powdery solid which was recrystallized from <85% aqueous ethanol to give 65.5 g (63%) of white crystals, mp 191-22 ° C. / lit. mp 185-7<sup>s</sup>; JB Hendrickson et al. J. Am. Chem. Soo 86, 107 (1964J.7.
B. 4,5-Diphenylpyrrole-2,3-dicarboxylic acid
To a mixture of 57.5 g (0.172 mol) of dimethyl 4,5-diphenylpyrrole-2,3-dicarboxylate in 350 ml of methanol was added a solution of 71 g (1.78 mol) of sodium hydroxide in 350 ml of water. The mixture was heated at reflux for 2 hours, then cooled in an ice bath. The crystals
<img file="PT72087B_D0041.tif" />
Insoluble whites were pooled and washed with cold methanol to give the bis-sodium salt of the product. The still wet solid was dissolved in 1 liter of cold water and acidified with concentrated hydrochloric acid. The precipitated product was collected by filtration, washed with water containing 1% hydrochloric acid, then air dried and finally dried in a vacuum oven at 100% to give 50.0 g (95%) of white solid, mp 216 ° C. -2189 (decomposition, depends on heating rate).
CL 2,3-Diphenylpyrrole (Process A)
A mixture of 20 g (0.065 mol) of 4,5-diphenylpyrrole-2,3-dicarboxylic acid in 80 ml of quinoline was refluxed in an oil bath (bath zv2309) until gas evolution had stopped (approximately 1 hour and a half). The reaction mixture was cooled and most of the quinoline was distilled off (bp 589 under 0.2 min). 0 Partially crystalline residue was chromatographed over 300 g of Silica; AR CC-7, eluting with toluene to give 12 g (85%) of slightly pink 2,3-diphenylpyrrole which could be further purified by recrystallization from. ethanol / water or by sublimation (^ vi25<sup>s</sup> 0.2 mm) to give a white solid, mp 132-3 ° C.<sup>2</sup>.
Analysis: C<sub>The</sub>calculated for: 0.87.64; H 5.98; N, 6.39
Found: C, 87.99; H 5.86; N, 6.50.
Preparation 2
2,3-Diphenylpyrrole (Process B)
A. Glyoxal mono (dimethylldrazone) was prepared by the process of T. Severin and H. Poehlmann, Ohem, Ber., 110, 491 ((1977)) to give 36.1 g (80%) of pale yellow liquid, e.g. 109<sup>2</sup> (22 mm); lit. eg 909 (16 mm).
B. 4-Jimethylhydrazono-12-diphenyl-2-butene-1-one
To a mixture of 19.6 g (0.1 mole) deoxybenzoin and 10 g (0.1 mole) glyoxal mono (dimethylhydrazone) in 100 ml ethanol was added dropwise a solution of sodium ethoxide prepared by dissolving 2 0.3 g (0.1 mol) of metallic sodium in 100 ml of ethanol. The mixture was heated to reflux.
<img file="PT72087B_D0042.tif" />
for one and a half hours. Thin layer chromatogram (90/10, toluene / ethyl acetate) showed a small amount of starting deoxybenzoin; thus 2.0 g (0.02 mol) of additional mono (dimethylhydrazone) glyoxal was added. Heating was continued for a further 2 hours. The thin layer chromatogram at this time showed no starting material and showed two near-clean yellow product spots (isomers). The mixture was poured into 1 liter of ice water and then extracted with methylene chloride. The organic extracts were dried and concentrated on a rotary evaporator to give 28.7 g (100%) of yellow oil. Nuclear magnetic resonance spectrum showed the presence of two major materials containing N (CH<sub>3</sub>)<sub>2</sub> (product isomers) '. The crude oil crystallized from isopropanol to give a pure isomer of the product,
13.4 g (48%), pale yellow crystals, mp 131-22 ° C.
Analysis: Calculated for: θιθΗ ^ θ ^ Ο; 0.77.67; H 6.52;
N, 10.06;
Found: C, 77.44; H 6.46; N, 10.77.
0 2,3-Piphenylpyrrole (Process B)
A mixture of 3.1 g (0.011 mol) of 4-dimethylhydrazono-1,2-diphenyl-2-butene-1-one, 11.2 g (0.064 mol) of sodium hydrosulfite in 75 ml of ethanol and 37, 5 ml of water was heated at reflux for 3 hours. The mixture was cooled and poured into 300 ml of ice water. The white crystalline product was combined, washed with water and air dried to give 1.9 g (79%), mp 130-12 ° C, identical to the product obtained by decarboxylation, Process A.
Preparation 3
4,5-Diphenyl-3-methylpyrrole
A. Ethyl 4,5-diphenylpyrrole-3-oboxylate was prepared by a similar process to that used by AM van Leusen et al., Tet, letters, 5337 (1972) for the preparation of methyl ester. The ethyl ester was obtained as a white solid, mp 207-208.5 ° C.<sup>3</sup> (methylcyclohexane / toluene),
Analysis: Calculated for: Ο ^ Η ^ γΝΟ; C, 78.33; H, 5.88; N, 4.81.
Found: C, 77.92; H 5.87; H 4.60
77,90 5,88 4,62
- í ',.? · titi,
'.y. · -. * · Λ
<img file="PT72087B_D0043.tif" />
<sup>:</sup>;you
<img file="PT72087B_D0044.tif" />
B. 4,5-Diphenyl-3-methylpyrrole
To a stirred mass of 0.76 g (20 millimoles) of aluminum hydride in 25 ml of THE was added dropwise a solution of ethyl 4,5-diphenylpyrrole-3-carboxylate 0.58 g (2 millimoles). in 5 ml of THE. The mixture was heated at reflux overnight. After cooling 0.8 ml of water, 2.4 ml of 15% sodium hydroxide solution and 0.8 ml of water were added dropwise. The solids were removed by filtration and the filtrate concentrated by rotary evaporation. 0 The crystalline residue was purified by chromatography on 50 g of Silica AR CC-7, eluting with hexane / toluene (90/10) to give 0.25 g of product, m.p. 163-4<sup>2</sup>.
Analysis: Calculated for: H ^H H ^N; 0.87.51; H 6.48
11,6,00
Found: C, 87.77; H 6.60; N 5.89
Preparation 4
<img file="PT72087B_D0045.tif" />
4,5-Bis (4-chlorophenyl) -3-propylpyrrole
A. 2-Acetylthio-3-allyl-4,5-bis (4-chlorophenyl) pyrrole
A solution of 3.6 g (0.01 mol) of 2-allylthio-4,5-bis (4-chlorophenyl) pyrrole in 20 ml of acetic anhydride was added dropwise to 20 ml of quinoline previously heated to 170 ° C.<sup>2</sup>. The mixture was kept at 170 ° C.<sup>2</sup> for an additional 45 minutes and then cooled. Most acetic acid, acetic anhydride and quinoline were distilled off under reduced pressure. The residue was chromatographed on 125 g of Silica AR CC-7, eluting with toluene, to give after recrystallization from hexane / methylcyclohexane, 2.7 g of white product, mp 131-22 ° C.
Analysis: Calculated for: .Οο-, Η - ,, γΟίΓ, ΗΌδ; C, 62.69;
H, 4.26; H, 3.48
Found: C, 62.48; H, 4.47; H, 3.57.
B. 4,5 - Bis- (4-chlorophenyl) -3-propylpyrrole
A mixture of 5 g Raney Nickel, 0.8 g (2 ml
<img file="PT72087B_D0046.tif" />
2-acetylthio-3-allyl-4,5-bis (4-chlorophenyl) pyrrole and 50 ml of acetone was heated at reflux under nitrogen for 2 hours. The mixture was diluted with ethanol and the catalyst was removed by filtration. The filtrate was concentrated by rotary evaporation. The residue was purified by chromatography on 50 g of Silic AR CC-7, eluting with hexane / toluene (90/10) to give 0.15 g of white crystals mp 90.93 ° C.<sup>The</sup>.
Mass Spectrum Calculated for: 19<sup>H</sup>17<sup>NC1</sup>2<sup>5</sup>
Found:
329,0738.
329,0759.
Other 2,3-diarylpyrroles prepared by this process are shown in Table I.
Table I
2,3-Eiarylpyrroles
<img file="PT72087B_D0047.tif" />
Air Preparation
Air'
R,
<td>4-OH<sub>3</sub>OO<sub>6</sub>B<sub>4</sub></td><td>4-ch<sub>3</sub>oc<sub>6</sub>H<sub>4</sub></td><td>H</td>
<td>4-IC<sub>6</sub>H<sub>4</sub></td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>H</td>
<td> 4-010<sub>6</sub>B<sub>4</sub></td><td>4-ClC<sub>6</sub>H<sub>4</sub></td><td>H</td>
<td>4 -0<sub>6</sub>Η<sub>4</sub></td><td>4c<sub>2</sub>H<sub>5</sub>0C<sub>6</sub>H<sub>4</sub></td><td>H</td>
<td> 4-010<sub>6</sub>H<sub>4</sub></td><td>4-P0<sub>6</sub>H<sub>4</sub></td><td>H</td>
<td>Ψ-εο<sub>6</sub>η<sub>4</sub>·</td><td>4-ClC<sub>6</sub>H<sub>4</sub></td><td>H</td>
<td>4-io<sub>6</sub>H<sub>4</sub></td><td>4-CH<sub>3</sub>OCgH<sub>4</sub></td><td>H</td>
<td> 4-010<sub>6</sub>H<sub>4</sub></td><td>4 am<sub>3</sub>0C<sub>6</sub>H<sub>4</sub></td><td>H</td>
<td>4-W<sub>s</sub>H<sub>4</sub></td><td> °6<sup>H</sup>5</td><td>H</td>
<td> 4-010<sub>6</sub>H<sub>4</sub></td><td> °6<sup>H</sup>5</td><td>H</td>
Melting point oil
119,5-120,5®
124-127®
118-118,5®
102-104®
116-1182
117-1182
105-1102
137-1382
124-1262
Table 1 - continued
2,3-Diarylpyrroles
<img file="PT72087B_D0048.tif" />
Preparation Air Ar 'Melting Point
<td> 15</td><td><sup>4</sup>-°<sup>H</sup>3<sup>ç</sup>6<sup>H</sup>4</td><td>4 ° h<sub>3</sub>ç<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 128-129<sup>The</sup></td>
<td> 16</td><td>3-EN<sub>6</sub>H<sub>4</sub></td><td>3-ec<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 90-90,52</td>
<td> 17</td><td><sup>G</sup>6<sup>H</sup>5</td><td>3,4-diClCgHg</td><td>H</td><td> 112-1132</td>
<td> 18</td><td>2-PG<sub>6</sub>H<sub>4</sub></td><td>2-P0<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 131-132,52</td>
<td> 19</td><td>g<sub>6</sub>H<sub>5</sub></td><td>3-pyridyl</td><td>H</td><td>190-192S</td>
<td> 20</td><td>4-CH<sub>3</sub>0C<sub>6</sub>H<sub>4</sub></td><td>2-thienyl</td><td>H</td><td> 65-66,52</td>
<td> 21</td><td><sup>G</sup>6<sup>H</sup>5</td><td>4-CH<sub>3</sub>00<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 77-77,52</td>
<td> 22</td><td></td><td>4-BrC<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 129-1302</td>
<td> 23</td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>4- (0H<sub>3</sub>)<sub>2</sub>N0<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 200-2012</td>
<td> 24</td><td><sup>G</sup>6<sup>H</sup>5</td><td>4-E0<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 105,5-106,52</td>
<td> 25</td><td> °6<sup>H</sup>5</td><td>4-C10<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 100-1012</td>
<td> 26</td><td>4_C1C<sub>6</sub>H<sub>4</sub></td><td> 3-010<sub>6</sub>H<sub>4</sub></td><td>H</td><td>oil</td>
<td> 27</td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>4 am<sub>3</sub>S0<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 164-1652</td>
<td> 28</td><td>4-FC<sub>6</sub>H<sub>4</sub></td><td>2-thienyl</td><td>H</td><td> 97-992</td>
<td> 29</td><td>4-PC<sub>6</sub>H<sub>4</sub></td><td>3-pyridyl</td><td>H</td><td> 173-1742</td>
<td> 30</td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>4-oh<sub>3</sub>only<sub>2</sub>ç<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 268-2702</td>
<td> 31</td><td>4-C10<sub>6</sub>H<sub>4</sub></td><td>4-010gH<sub>4</sub></td><td>oh<sub>3</sub></td><td> 132-1422</td>
<td> 32</td><td>4-P0gH<sub>4</sub></td><td>4-PCgH<sub>4</sub></td><td>oh<sub>3</sub></td><td> 126-1272</td>
<td> 33</td><td>4-OHgOC<sub>6</sub>H<sub>4</sub></td><td>4 am<sub>3</sub>O0<sub>6</sub>H<sub>4</sub></td><td>oh<sub>3</sub></td><td>oil</td>
<td> 34</td><td>4-P0<sub>6</sub>H<sub>4</sub></td><td>4-PC<sub>6</sub>H<sub>4</sub></td><td>oh<sub>3</sub>(</td><td>3H<sub>2</sub>0H<sub>2</sub> 113-115</td>
<td>EXAMPLE 1</td><td></td><td></td><td></td><td></td>
<td>4,5-Diphenyl-</td><td colspan="3">2- (trifluoromethylthio) pyrrole</td><td></td>
In a flame-proof glass vessel under nitrogen and equipped with a dry ice condenser, 11 g (0.05 mol) of 2,3-diphenylpyrrole ', 6.2 g (0.06 mol) were placed. of anhydrous sodium carbonate and 200 ml of ether.
The mixture was cooled to -3020 ° C and 7.6 g (0.055 mol) of clc.
<img file="PT72087B_D0049.tif" />
Trifluoromethanesulfenylamide were added as a gas from a tared siphon. The reaction mixture was stirred at -30 ° C.<sup>The</sup> for half an hour and then allowed to warm to room temperature over 2 hours. Inorganic salts were removed by filtration and the ethereal filtrate was concentrated. of. The residue was chromatographed on 300 g of Silic AR CC-7 eluting with hexane containing 5-10% toluene. The product was obtained as a white solid, 15.4 g (96%) mp 58-9 ° C.<sup>The</sup>.
Analysis: Calculated for: Cq ^Hqgl ^ ^Rí »63.94} H, 3.79}
R, 4.39
Found: C, 63.66} H, 3.87} R, 4.34.
EXAMPLE 2
4,5-Bis (4-methoxyphenyl) -2- (trifluoromethylthio) pyrrole (process
THE)
Following the procedure of Example 1, the reaction of
2,3-bis (4-methoxyphenyl) pyrrole with trifluoromethanesulfenyl chloride gave 4,5-bis (4-methoxyphenyl) -2-trifluoromethylthio2 pyrrole as a white solid, mp 114-115 ° C<sup>2</sup>.
Analysis: Calculated for: CqgHqgE ^OgS: C, 60.14; H, 4.25;
R 3.69.
Found: 0.60.24} H, 4.29} R, 3.67
60,32 4,20 3,71.
Process B (a) 4,5-Bis (4-methoxyphenyl) pyrrole-2-carboxaldehyde
At 25 ml of EME at 0<sup>The</sup> 30 g of phosphorus oxychloride were added dropwise with stirring. The mixture was stirred for 15 minutes at room temperature; then a solution of 5.6 g (0.02 mol) of 2,3-bis (4-methoxyphenyl) pyrrole in 40 ml of EME was added dropwise with cooling on an ice bath. The mixture was then heated to 70-80 ° C.<sup>2</sup> for 1 hour and then cooled. Aqueous sodium hydroxide (50%) was added until the basic strand mixture. The reaction mixture was then heated again to 70 ° C.<sup>The</sup> for 15 minutes. The cooled reaction mixture was poured into ice water. The precipitated material was pooled and purified by chromatography.
<img file="PT72087B_D0050.tif" />
over 600 g of Silic AR 00-7 (eluting with toluene containing 1-2% ethyl acetate) to give 3.4 g (55 of product, mp 164-1662 ° C (methylcyclohexane / toluene).
Analysis: Calculated for C C íH ^ ^NO NO: C, 74.25; H, 5.58;
N 4.56
Found: C, 74.46; H 5.43; N, 4.44.
(b) 4,5-Bis (4-methoxyphenyl) -2- (trifluoromethylthio) -pyrazole
To a stirred mixture of 1.5 g (5 millimoles) of
4,5-bis (4-methoxyphenyl) pyrrole-2-carboxaldehyde and 1.3 g sodium carbonate in 10 ml ether / 10 ml THE at -782 was added O 3 g trifluoromethanesulfenyl chloride. The mixture was allowed to warm to room temperature with a dry ice condenser attached to keep the trifluoromethanesulfenyl chloride from escaping. Excess trifluoromethanesulfenyl chloride was added and the mixture was stirred overnight at room temperature. The mixture was filtered and the filtrate concentrated by rotary evaporation. The residue was purified by chromatography on 300 g of Silic AR 00-7, eluting with toluene to give 0.75 g (39%) of the product, as obtained by process A.
Process C (a) 4,5-Bis- (4-methoxyphenyl) -2- (trifluoroacetyl) pyrA A stirred solution of 2.5 g trifluoroacetic anhydride in 30 ml ether at 0 ° C was added dropwise a solution of 2 0.8 g (0.01 mol) 2,3-bis- (4-methoxyphenyl)<sub>< </sub>pyrrole and 1.5 g of dimethyl aniline in 20 ml of ether. The mixture was stirred for 1 hour at 0 ° C, then diluted with further ether and washed with water, 1N hydrochloric acid and then again with water. The organic layer was dried and concentrated. The residue was purified by chromatography on Silic AR 00-7 (300 g eluting with good toluene), followed by recrystallization from methylcyclohexane to give 2.2 g (59%) of pale yellow crystals, m.p. 185-186.5<sup>2</sup>
Analysis: Calculated for: ^ 20 ^ 16 ^ 3 ^ 3<sup>:</sup> θ '4.00; H, 4.50;
N, 3.73.
<img file="PT72087B_D0051.tif" />
Found: C, 64.35; H, 4.41} N, 3.61
64.03 4.22 3.70 (b) 4,5-Bis (4-Methoxyphenyl) pyrrole-2-carboxylic acid
To a solution heated to reflux of 1.9 g (5 millimoles) of 4,5-bis (4-methoxyphenyl) -2- (trifluoroacetyl) pyrrole in 20 ml of ethanol was added a solution of 2 g of sodium in 20 ml of water. The mixture was heated at reflux for 31/2 hours, then cooled and diluted with water. The aqueous solution was extracted with methylene chloride. The aqueous layer gave only 0.1 g of acid product after acidulation with hydrochloric acid. The methylene chloride solution of the acid sodium salt was acidulated by stirring with 1N hydrochloric acid. The methylene chloride layer was then each and concentrated to give an additional 1.1 g of acid product.
The combined product was recrystallized from ethanol / water to give 1.2 g (75%) of white product, mp 204-205 ° C.<sup>2</sup>.
Analysis: Calculated for: C ^ HH ^ NONO ^: C, 70.58} H, 5.30
N, 4.33
Found: 0.70.38; H, 5.35; N, 4.44.
(c) 4,5-Bis (4-methoxyphenyl) -2- (trifluoromethylthio) pyrrole
To a solution of 0.3 g (1 millimole) of 4,5α-bis (4-methoxyphenyl) pyrrole-2-carboxylic acid in 5 ml ether / 5 ml THE at -78 ° C<sup>The</sup> 0.3 g of trifluoromethanesulfenyl chloride was added as a gas. After 15 minutes, the thin layer chromatogram showed no reaction signal, so a large excess of trifluoromethanesh chloride. phenyl was added and the mixture was allowed to slowly warm to room temperature overnight with a dry ice condenser on for the first few hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by chromatography on 100 g of Silic AR 00-7 to give, after recrystallization from hexane, 0.15 g (40 of 4,5-bis (4-methoxyphenyl)). (Trifluoromethylthio) pyrrole, identical to the product obtained by Process A.
Other 4,5-diaryl-2- (trifluoromethylthio) pyrroles prepared by the processes of Examples 1 and 2A are shown in Table II.
'·-
<img file="PT72087B_D0052.tif" />
k<sup>:</sup>-<
//¾
<img file="PT72087B_D0053.tif" />
;’ ···;
/ ·: · D-
<img file="PT72087B_D0054.tif" />
d '' í »
Γ · '·
Table II
4,5-Sialyl-2- (trifluoromethylthio) pyrrole
<img file="PT72087B_D0055.tif" />
<td colspan="3">Air</td><td colspan="2" rowspan="2">Λ<sup>X</sup>^ SOE<sub>3</sub></td>
<td rowspan="2">Example</td><td rowspan="2">Air</td><td rowspan="2">H Air'</td>
<td><sup>AND</sup>4</td><td>Melting Point</td>
<td> 3</td><td>4-po<sub>6</sub>H<sub>4</sub></td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 106-107,5<sup>2</sup></td>
<td> 4</td><td> 4-010<sub>6</sub>H<sub>4</sub></td><td>4-ClC<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 95-96,5<sup>2</sup> .</td>
<td> 5</td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>4c<sub>2</sub>H<sub>5</sub>0C<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 83-842</td>
<td> 6</td><td>4-ClCgH<sub>4</sub></td><td>4-.EO<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 103-104<sup>2</sup></td>
<td> 7</td><td>4 ~ E0<sub>6</sub>H<sub>4</sub></td><td>4-σισ<sub>6</sub>Η<sub>4</sub></td><td>H</td><td> 90-912</td>
<td> 8</td><td>4-E0<sub>6</sub>H<sub>4</sub></td><td>4-CH<sub>3</sub>0C<sub>6</sub>H<sub>4</sub> .</td><td>H</td><td> 122-1232</td>
<td> 9</td><td>4-ClC<sub>6</sub>H<sub>4</sub></td><td>4-CH<sub>3</sub>0C<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 115-116,52</td>
<td> 10</td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td><sup>: Ç</sup>6<sup>H</sup>5</td><td>H</td><td> 78-79<sup>2</sup></td>
<td> 11</td><td>4-ClC<sub>6</sub>H<sub>4</sub></td><td> °6<sup>H</sup>5</td><td>H</td><td> 98-992</td>
<td> 12</td><td>4-CH<sub>3</sub>Ç<sub>6</sub>H<sub>4</sub></td><td>4-ch<sub>3</sub>ç<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 79-802</td>
<td> 13</td><td>3-EO<sub>6</sub>H<sub>4</sub></td><td>3-EC<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 74-752</td>
<td> 14</td><td>4-01C<sub>6</sub>H<sub>4</sub></td><td>4-GlC<sub>6</sub>H<sub>4</sub></td><td>CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub></td><td> 99-1002</td>
<td> 15</td><td> °6<sup>H</sup>5</td><td> °6<sup>H</sup>5 .</td><td>gh<sub>3</sub></td><td> .79-812</td>
<td> 16</td><td> °6<sup>H</sup>5</td><td>3,4-diClC<sub>6</sub>H<sub>3</sub></td><td>H</td><td> 82-82,52</td>
<td> 17</td><td> °6<sup>H</sup>5</td><td>3-pyridyl</td><td>H</td><td> 196-1972</td>
<td> 18</td><td>4-CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub></td><td>2-thienyl</td><td>H</td><td> 73-742</td>
<td> 19</td><td>2-ECgH<sub>4</sub></td><td>2 -0<sub>6</sub>Η<sub>4</sub></td><td>H</td><td> 31-322</td>
<td> 20</td><td><sup>Ç</sup>6<sup>H</sup>5</td><td>4-CH<sub>3</sub>0C<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 107-1082</td>
<td> 21</td><td>4-ec<sub>6</sub>H<sub>4</sub></td><td>4-BrC<sub>6</sub>H<sub>4</sub></td><td>H '</td><td> 92,5-932</td>
<td> 22</td><td>4-W<sub>6</sub>H<sub>4</sub></td><td colspan="2">4- (ch<sub>3</sub>)<sub>2</sub>nc<sub>6</sub>H<sub>4</sub>H</td><td> 158-159,52</td>
<td> 23</td><td> °6<sup>H</sup>5</td><td>4k<sub>5</sub>H<sub>4</sub></td><td>H</td><td> 88-88,52</td>
.
<img file="PT72087B_D0056.tif" />
<td>T abe</td><td colspan="2">1 to II (continued)</td><td></td><td></td>
<td>Example</td><td>Air</td><td>Air'</td><td>B</td><td>Point of fue</td>
<td> 24</td><td> °6<sup>H</sup>5</td><td>4-ClC<sub>g</sub>H<sub>4</sub></td><td>H</td><td> 107-1082</td>
<td> 25</td><td>3-ClC<sub>6</sub>H<sub>4</sub></td><td>3-ClC<sub>6</sub>H<sub>4</sub></td><td>H</td><td>oil</td>
<td> 26</td><td>4-FCgH<sub>4</sub></td><td>4-CH<sub>3</sub>SC<sub>6</sub>! í<sub>4</sub></td><td>H</td><td> 106-1072</td>
<td> 27</td><td> 4-¾</td><td>2-thienyl</td><td>H</td><td> 65-662</td>
<td> 28</td><td>4-FC<sub>6</sub>H<sub>4</sub></td><td>3-pyridyl</td><td>H</td><td> 190-1912</td>
<td> 29</td><td> 4-¾</td><td>4-CH<sub>3</sub>S0<sub>2</sub>Ç<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 203-204-</td>
<td> 30</td><td>4-ClC<sub>6</sub>H<sub>4</sub></td><td>4-cic<sub>6</sub>H<sub>4</sub></td><td>ch<sub>3</sub></td><td> 87-902</td>
<td> 31</td><td>4-FC<sub>6</sub><sup>H</sup>4</td><td>4-FC<sub>6</sub>H<sub>4</sub></td><td>ch<sub>3</sub></td><td> 125-125,5<sup>2</sup></td>
<td> 32</td><td>4-CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub></td><td>4-CH<sub>3</sub>0C<sub>6</sub>H<sub>4</sub></td><td>oh<sub>3</sub></td><td> 132-133<sup>3</sup></td>
<td> 33</td><td>4-F0<sub>6</sub>H<sub>4</sub></td><td>4-fc<sub>6</sub>H<sub>4</sub></td><td>CH<sub>3</sub>CH<sub>2</sub>CH<sub>2</sub></td><td> 96,5-97<sup>3</sup></td>
Preparation 35
4,5-Diphenyl-2- (thiooylate) pyrrole)
To a mixture of 11 g (0.05 mole) 2,3-diphenylpyrrole in 150 ml methanol at room temperature was added portionwise 18 g (r / 0.1 mol) cupric thiocyanate. After stirring at room temperature for 3 hours, the thin layer chromatogram indicated that approximately 50% of starting material was unreacted (no change for 2 hours) so that another 18 g (0.1 mol) of cupric thiocyanate was removed. added. After a further 1 hour, the thin layer chromatogram indicated no starting material. The inorganic material was removed by filtration and the methanolic filtrate was concentrated. This residue was taken up in methylene chloride, washed with water, then dried and concentrated. The residue was chromatographed over 300 g of Silic AR CC-7 eluting with toluene to give 11.3 g (82%) mp 139-14-02 ° C (methylcyclohexane).
Analysis: Calculated for: <sup>ç</sup>i7<sup>H</sup>i2 ^ 2®<sup>!</sup> θ 73.89; H, 4.38
R, 10.14
0, 73.90; H, 4.49; N, 10.31.
Found:
<img file="PT72087B_D0057.tif" />
Other 4,5-diaryl-2- (thiocyanate) pyrroles prepared in this manner are shown in Table III.
Table III
4,5-Diaryl-2- (thiocyanate) pyrroles
<img file="PT72087B_D0058.tif" />
Air Preparation
Fusion point
4-GH<sub>3</sub>0G<sub>6</sub>H<sub>4</sub>
4-FC<sub>6</sub>H<sub>4</sub>
4-ClCgH<sub>4</sub>
4-FC<sub>6</sub>H<sub>4</sub>
4-ClCgH<sub>4</sub>
4-FC<sub>6</sub>H<sub>4</sub>
4-FC<sub>6</sub>H<sub>4</sub>
4-hello<sub>6</sub>H<sub>4</sub>
4-FC<sub>6</sub>H<sub>4</sub>
4-GlC<sub>6</sub>H<sub>4</sub>
4-CH<sub>3</sub>Ç<sub>6</sub>H<sub>4</sub>
Air'
<td>4 am<sub>3</sub>0C<sub>6</sub>H<sub>4</sub></td><td>oil</td>
<td>4c<sub>2</sub>H<sub>5</sub>0G<sub>6</sub>H<sub>4</sub></td><td> 129-1312</td>
<td>4-ClG<sub>6</sub>H<sub>4</sub></td><td> 168-169<sup>2</sup></td>
<td>4-FC<sub>6</sub>H<sub>4</sub></td><td> 164-165,5<sup>2</sup></td>
<td>4-F0gH<sub>4</sub></td><td> 150-159<sup>2</sup></td>
<td>4-0lC<sub>6</sub>H<sub>4</sub></td><td> . 174-175<sup>2</sup></td>
<td>4-ch<sub>3</sub>oc<sub>6</sub>H<sub>4</sub></td><td> 148-1492</td>
<td>4-CH<sub>3</sub>OC<sub>6</sub>H<sub>4</sub></td><td> 173-1742</td>
<td><sup>Ç</sup>6<sup>H</sup>5</td><td> 175-1763</td>
<td><sup>Ç</sup>6<sup>s</sup>5</td><td> 162-162,52</td>
<td>4-CH<sub>3</sub>Ç<sub>6</sub>H<sub>4</sub></td><td> 161-1622</td>
EXAMPLE 34
4,5-Diphenyl-2- (methylthio) pyrrole
To a mixture of 1.4 g (0.005 mol) of 2,3-diphenyl-5-thiocyanatopyrrole, 0.85 g (0.006 mol) of methyl iodide in 10 ml of methanol was added dropwise at 3 ° C. 0.8 g (0.012 mol, 85%) of potassium hydroxide in 5 ml of water + 5 ml of methanol. The mixture was left to warm
<img file="PT72087B_D0059.tif" />
to room temperature, then poured into 100 ml of ice water and neutralized with hydrochloric acid. The aqueous mixture was extracted with methylene chloride and the extracts dried and concentrated. The residue was chromatographed on 50 g of Silic AR. CC-7 and eluted with toluene to give 1.2 g (90%) of yellow oil.
Example 36
4.5- Bis- (4-fluorophenyl) -2- (1,1,2,2-tetrafluoroethylthio) pyrrole
A mixture of 3.1 g (0.01 mol) of 4,5-bis (4-fluorophenyl) -2- (thiocyanate) pyrrole, 10 ml ... of water and 100 ml ethanol was placed in a sturdy well. The pressure is frozen in a dry ice bath. Then 2.0 g of potassium hydroxide was added. The pressure resistant flow was evacuated and purged with nitrogen. Then 2.5 g of tetrafluoroethylene was added and the pressure resistant flow sealed. The mixture was allowed to warm to room temperature and was stirred overnight. 0 Pressure resistant flow was vented and the contents were dragged off with methanol. The mixture was diluted with water and saturated sodium chloride solution and then extracted with methylene chloride. The organic layers were combined, dried and concentrated by rotary evaporation. The residue was chromatographed over 300 g of Silic AR CC-7 eluting with mixtures of hexane and toluene to give after recrystallization from hexane or ethanol / water, 1.8 g of m.p.
70.5- 712.
Analysis: Calculated for C C ^H-QFNSNSS: C, 55.82; H, 2.86
N, 3> 62
Found: C, 55.78; H, 3.08; N, 3.48.
Other 4,5-diaryl-2- (alkylthio) pyrroles prepared in this manner are shown in Table IV.
'vsr'
<img file="PT72087B_D0060.tif" />
X *>. C. ':
<img file="PT72087B_D0061.tif" />
ο
ICti ra «ΗΗ ©
no
P ι — IP = io
rH &
ω
M a
Hello in ”hi hi
In in
<td>Hello</td><td colspan="2">Hello</td><td>CM</td><td colspan="2">Hello</td><td colspan="2"> ·*</td><td> *</td><td>Hello</td>
<td>tn</td><td></td><td>rH</td><td>H</td><td></td><td>in</td><td></td><td>CM</td><td>CM</td><td>in</td>
<td>GRANDFATHER</td><td>Hello</td><td></td><td> 1</td><td>O</td><td></td><td>O</td><td>rH</td><td>O</td><td>O</td>
<td>H</td><td>m</td><td>H</td><td>in</td><td> ©</td><td> 00</td><td> ©</td><td>rH</td><td>H</td><td>H</td>
<td> 1</td><td>oo</td><td>J</td><td> —</td><td>rH</td><td>oo</td><td>rH</td><td>I</td><td> |</td><td> 1</td>
<td> <*</td><td> 1</td><td>ΟΛ</td><td>cn</td><td>Ό</td><td> 1</td><td>Ό</td><td>CM</td><td>CM</td><td>QC</td>
<td>GRANDFATHER</td><td>CM</td><td>m</td><td>I-t</td><td></td><td>m</td><td></td><td>rH</td><td>O</td><td>O</td>
<td>rH</td><td> 00</td><td>rH</td><td>rH</td><td></td><td>oo</td><td></td><td>rH</td><td>rH</td><td>rH</td>
Coω co o
O
CM a
om
Mo o
M · a
with the
O
ΓΟ a
O
CM
P4
O
CM
CO
CM a
om
W o
a * co o
the in a
co
<td>ΓΠ</td><td>no</td><td>O</td><td>The</td><td>O</td><td>CD</td><td>O</td><td>CO</td><td>O</td>
<td>The</td><td>The</td><td>rH</td><td>CM</td><td>rH</td><td>O</td><td>H</td><td>O</td><td>H</td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>PH</td><td>O</td><td></td><td>O</td>
<td>1 'd-</td><td> 4-</td><td>1 'd-</td><td> 4</td><td> 4</td><td> 4</td><td>1 Ή-</td><td> 1</td><td> 4</td>
, 'Φ a
with the
O n
to
I
-d-
<td>Ή-</td><td colspan="9">Ή ·</td>
<td>The</td><td>The</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>co</td><td>co</td><td>Ή-</td><td></td><td>* xh</td><td></td><td>'d-</td><td></td><td></td><td></td>
<td>O</td><td>O</td><td>The</td><td>sf-</td><td>The</td><td>• M-</td><td>The</td><td>The</td><td>-d-</td><td>'t</td>
<td>O</td><td>O</td><td>co</td><td>w</td><td>co</td><td>The</td><td>co</td><td>CD</td><td>The</td><td>The</td>
<td>m</td><td>ΓΟ</td><td>O</td><td>co</td><td>O</td><td>co</td><td>O</td><td>O</td><td>co</td><td>co</td>
<td>The</td><td>The</td><td>rH</td><td>O</td><td>H</td><td>O</td><td>H</td><td>rH</td><td>O</td><td>O</td>
<td>O</td><td>O</td><td>O</td><td>p4</td><td>O</td><td>Ph</td><td>O</td><td>O</td><td>(THE</td><td>P4</td>
<td>1 d-</td><td> 4</td><td> 4</td><td>1 'd<sup>-</sup></td><td> 4</td><td>1 d-</td><td>1 'd-</td><td> 4</td><td> 4</td><td>1 d</td>
with
c- οο σ> ommm «d ·
H cm ro - = 4- IPi * d * 'í · Ή- «d- dIV (continued
A <D fi ctí
M
(D
THE
O
Pt • rl
P
O
Ή
P
A • r | σ
THE
ASS
I
CM
H • H a
•H
THE
I in
<img file="PT72087B_D0062.tif" />
ο κβ ra rf
A <1>
THE
O • P
Pi o
PM
$ 1 o
A ω
M
Hi
Lf \
<td colspan="2">Hello</td><td> ·*</td><td colspan="2">Hello</td>
<td>THE</td><td></td><td>THE-</td><td> 00</td><td></td>
<td>tn</td><td>Hello</td><td>CM</td><td>THE</td><td>O</td>
<td>THE</td><td>CO</td><td>THE</td><td>THE</td><td>(D</td>
<td> 1</td><td>cn</td><td> 1</td><td> 1</td><td>THE</td>
<td>ΟΊ</td><td> 1</td><td></td><td> [·-</td><td>*O</td>
<td>THE-</td><td>r-</td><td>CM</td><td>THE</td><td></td>
<td>THE</td><td>cn</td><td>H</td><td>THE</td><td></td>
W
O
Mo o
II cn cn cn cn cm
MWWWW ooooo
A W
CD
O
The m
W o
<td></td><td></td><td>THE-</td><td></td>
<td></td><td></td><td>M</td><td>THE-</td>
<td></td><td></td><td>CD</td><td>W</td>
<td></td><td></td><td>O</td><td>co</td>
<td></td><td></td><td>CO</td><td>O</td>
<td>tn</td><td>. L3</td><td>w</td><td>THE</td>
<td>W</td><td>w</td><td>O</td><td>O</td>
<td>CD</td><td>CD</td><td>l</td><td>l</td>
oo
<td>THE-</td><td></td><td>THE-</td><td>w<sup>1</sup></td><td>THE-</td>
<td>w</td><td>THE-</td><td>W</td><td>CO</td><td>w</td>
<td>co</td><td>W</td><td>CD</td><td>O</td><td>CD</td>
<td>O</td><td>co</td><td>O</td><td>cn</td><td>O</td>
<td>THE</td><td>O</td><td>THE</td><td>W</td><td>THE</td>
<td>O</td><td>THE</td><td>O</td><td>O</td><td>O</td>
<td> 4-</td><td>1 THE-</td><td>1 THE-</td><td> 4</td><td> 4</td>
co cco cn A · A- AA
The tn
EXAMPLES 51, 52
4,5-Diphenyl-2- (trifluoromethylsulfonyl and sulfinyl) pyrrole:<sup>z</sup>4 \·
7. .
Κ<sup>1</sup>
<img file="PT72087B_D0063.tif" />
To a solution of 9.6 g (0.03 mol) of 4,5-diphenyl-2- (trifluoromethylthio) pyrrole in 100 ml of methylene chloride at room temperature was added dropwise a solution of 12 g (w / w). 0.06 mol, ΔA / 85%) of m-chloroperoxybenzoic acid in 150 ml of methylene chloride. After 2 hours, the thin layer chromatography assay (toluene / ethyl acetate, 90/10) showed traces of sulfide and higher amounts of sulfoxide and sulfone. Since a potassium starch iodide assay was negative, an additional 1 g (<V0.005 mole) peracid was added and stirring continued for a further 2 hours negative KI-starch assay; thin layer chromatography assay, absence of sulphide). The mixture was washed twice with 10% sodium bicarbonate ume. once with water, and then dried and concentrated. The residue was chromatographed on Λ / 1 kg Silic AR OC-7. The sulfone was eluted with toluene, 2.2 g (22%), mp 159-160 ° C (methylcyclohexane), example 51.
Analyze:
N, 3.99.
Found: C, 58.25; H, 3.60; ΪΓ 4.39
Calculated for:
<sup>G</sup>17<sup>H</sup>12<sup>P</sup>3<sup>W0</sup>2<sup>Sí</sup>
C, 58.12; H, 3.44;
sulfoxide was eluted with toluene / ethyl acetate (95/5), 0.9 g (9%), mp 125-6 ° C.<sup>2</sup> (ethanol / water) example 52.
Analysis: Calculated for: C16 H25 N4 O2: C, 60.89; H, 3.61;
N, 4.18.
Found: C, 60.99, 61.37; H, 3.45, 4.12;
N, 3.94, 4.00.
Other 4,5-diaryl-2- (alkylsulfinyl and sulfonyl) pyrroles prepared in this manner are shown in Table V.
aj
Η
Φ
Π π5
Ε4
<img file="PT72087B_D0064.tif" />
ο w3 ra ΰ
Ή
Φ
Ο
Ρ
Ο
Ρ
<td>Ο!</td><td>ΟΙ</td><td colspan="4">Ο!</td><td colspan="2">ΟΙ</td>
<td>ΙΛ</td><td>ιη</td><td>ιη</td><td></td><td></td><td></td><td>ιη</td><td></td>
<td>Λ</td><td>λ</td><td> ·*</td><td>οι</td><td>οι</td><td>οι</td><td>Λ</td><td>ΟΙ</td>
<td>ρ-</td><td><Μ</td><td>νο</td><td>ιη</td><td>σ \</td><td>ιη</td><td>νο</td><td> 04</td>
<td>ο</td><td>P-</td><td>γπ</td><td>ιη</td><td> 04</td><td>γπ</td><td> [—</td><td>m</td>
<td>CVI</td><td>Ρ</td><td>Η</td><td>Η</td><td>Η</td><td>Η</td><td>Η</td><td>Η</td>
<td> 1</td><td> 1</td><td> 1</td><td> 1</td><td> 1</td><td> 1</td><td> 1</td><td> 1</td>
<td>γπ</td><td> 04</td><td>νο</td><td>Ρ-</td><td> 00</td><td>γΠ</td><td>νο</td><td>r4</td>
<td>ο</td><td>Ρ ·</td><td>γπ</td><td>ιη</td><td> 04</td><td>γη</td><td>t—</td><td>m</td>
<td> 04</td><td>Η</td><td>Η</td><td>Η</td><td>Η</td><td>Η</td><td>Ρ</td><td>Η</td>
m φ
Ο ο
F4 • Η
Ρ4
Ρ • Η £
• Η
Ρ
Ρ d
frog
04
04
Η 04 Η 04
Ή • Η d ο Ή Η 3 ra Η 3 σ Η Φ '- <I
<img file="PT72087B_D0065.tif" />
<td>ΓΠ</td><td>γπ</td><td>ΓΠ</td><td>ΓΠ</td><td>ΓΠ</td><td>Μ</td><td>ΓΠ</td><td>ΓΠ</td>
<td>Ρ</td><td>W</td><td>m</td><td>Ρ</td><td>Ρ</td><td>W</td><td>Ρ</td><td>Ρ</td>
<td>ο</td><td>ο</td><td>ο</td><td>ο</td><td>ο</td><td>ο</td><td>ο</td><td>ο</td>
4, • Η φ
• Η
Ρ
-=4
<td></td><td colspan="7"></td>
<td>Ρ-</td><td>P-</td><td>Ρ-</td><td></td><td></td><td></td><td></td><td>W</td>
<td>W</td><td>Μ</td><td>W</td><td></td><td></td><td></td><td></td><td>νο</td>
<td>νο</td><td>νο</td><td>νο</td><td></td><td></td><td>ρ-</td><td>Ρ-</td><td>ο</td>
<td>ο</td><td>Ο</td><td>ο</td><td>ν4</td><td>Ρ-</td><td>W</td><td>W</td><td>ο</td>
<td>ο</td><td>ο</td><td>ο</td><td>W</td><td>W</td><td>νο</td><td>νο</td><td>ιη</td>
<td>ΓΗ</td><td>γπ</td><td>γπ</td><td>νο</td><td>νο</td><td>ο</td><td>ο</td><td>hl</td>
<td>EH</td><td>W</td><td>Μ</td><td>Ο</td><td>ο</td><td>Ρ</td><td>Ρ</td><td>C4</td>
<td>ο I</td><td>ο</td><td rowspan="2">ο 4</td><td>Ρ I</td><td rowspan="2">Ρ 4</td><td>ο</td><td>ο</td><td rowspan="2">ο 4</td>
<td> 1</td><td> 4</td><td>1 Ρ-</td><td>1 Ρ-</td><td>1 Ρ-</td>
ι
Ιη
Ρ-
<td rowspan="2"></td><td rowspan="2">Ρ- Μ νο ο ο ηΓ ο</td><td colspan="7">P * p- WW</td>
<td>νο ο ο ΓΠ W ο</td><td>νο ο ο ΓΠ Μ ο</td><td>hT * · W νο ο Ρ</td><td>Μ * νο ο Ρ</td><td>νο ο Ρ ο</td><td>Μ * νο ο Ρ ο</td><td>w<sup>1</sup>νο α Ρ</td>
<td> & 1</td><td> 4</td><td> 4</td><td> 4*</td><td> 4</td><td> 4</td><td> 4</td><td> 4</td><td> 4</td>
<td> <4 1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
4-PCrH. 4-CoH-OCz-H. CS \ 1 166-169<sup>2</sup> ο
«Η<sup>1</sup> φ
£ γ γπ ιη pιη in νο ιη m trιη οο ιη cn ιη ο
νο
Ν νο ο
icon
Cn
Π3 d
laughs • rl
-P laughs
the rQ
Ώ (D
H
The laughs
0)
FM
H • H ri • H
Ή
H laughs
Γ — ι • H laughs
THE
H ri ra rd
H laughs
Hh
I
H • H o
I tn
<img file="PT72087B_D0066.tif" />
o »cd ra ri« H <D nj
O
-P laughs, the
THE.
tn tn
<td>Hello</td><td>Hello</td><td>Hello</td><td> ·%</td><td>Λ</td><td>Hello</td><td>Hello</td><td>Hello</td><td>Hello</td><td>Hello</td>
<td> 00</td><td>O</td><td>kO</td><td>tn</td><td>CM</td><td>cn</td><td>co</td><td>CM</td><td>cn</td><td>ΓΠ</td>
<td>CO</td><td>tn</td><td>CO</td><td> 00</td><td>I — 1</td><td>co</td><td> 00</td><td>THE</td><td>cn</td><td>«—L</td>
<td>r — I</td><td>rH</td><td>Ή</td><td>ϊ — í</td><td>CM</td><td>I — 1</td><td>H</td><td>CM</td><td>H</td><td>CM</td>
<td>1 CD</td><td>1 cn</td><td>1 m</td><td>1 in</td><td>1 CM</td><td></td><td>{ CM</td><td> 4)</td><td>co</td><td>1 CJ</td>
<td>C0</td><td>-Μ-</td><td>co</td><td> 00</td><td> -1</td><td>co</td><td>ω</td><td>H</td><td>cn</td><td>r-4</td>
<td>H</td><td>Η</td><td>H</td><td>r4</td><td>CM</td><td>H</td><td>H</td><td>CM-</td><td>H</td><td>CM</td>
ri | CMCMCMCMCMCMCMCMCM
CM fri m
tri o
C \ l
W o
m · m rri mmmm
WWMWW oooooo
rH <3 * ra «
• «4W with
ι — IO
I
4-4fcri * 4 * 4co ω tu emO Μ * -V CD CO w
ΨΗ 'ΨΗ -4- WOO MD intEj co M CD OOO
K co O ro ro ro cmohohWW tn W opqOAOOOW p IIIII 1 I co <1 -4--4 - = 4--4--4--4--4-0-4ri |
-d
<td></td><td></td><td></td><td> -4-</td><td> -4-</td><td></td><td></td><td> 4-</td><td> -4-</td>
<td>ω</td><td>xj-</td><td> 4-</td><td>w</td><td>w</td><td> -4-</td><td> -4-</td><td>w</td><td>M</td>
<td>kO</td><td>W</td><td>w</td><td>co</td><td>CD</td><td>w</td><td>w</td><td>co</td><td>co</td>
<td>O</td><td>CO</td><td>co</td><td>O</td><td>O</td><td>co</td><td>co</td><td>O</td><td>O</td>
<td>H</td><td>O</td><td>O</td><td>H</td><td>H</td><td>O</td><td>O</td><td>H</td><td>H</td>
<td>O</td><td>THE</td><td>THE</td><td>O</td><td>O</td><td>THE</td><td>THE</td><td>O</td><td>O</td>
<td> 1</td><td> 1 -4-</td><td> 1 -4-</td><td> 4-</td><td> 4-</td><td> 4-</td><td> 4-</td><td> 4</td><td> 4-</td>
with the
ro
W o
CM
C0 ro
CO
MCO tn co co c— co co co cn co HR CM
C t>
VI Table VI illustrates other compounds you may know.
<img file="PT72087B_D0067.tif" />
prepared by the processes described above.
Table VI
<img file="PT72087B_D0068.tif" />
<td> %</td><td>R,</td><td></td><td></td><td>no</td>
<td>-CH<sub>2</sub>GH = 0H<sub>2</sub></td><td>4-FC<sub>6</sub>H<sub>4</sub></td><td>4-FC<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 0</td>
<td>-OH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td><td>4-ch<sub>3</sub>oc<sub>6</sub>H<sub>4</sub></td><td>4-GH<sub>3</sub>OG<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 2</td>
<td>~ chf<sub>2</sub></td><td>4-FC<sub>6</sub>H<sub>4</sub></td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 0</td>
<td>-CF<sub>2</sub>0F<sub>3</sub></td><td>4-PCgH<sub>4</sub></td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 0</td>
<td>-ce<sub>3</sub></td><td>4-GlG<sub>6</sub>H<sub>4</sub></td><td>4-FG<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 2</td>
<td>-ch<sub>3</sub></td><td>4-F0<sub>6</sub>H<sub>4</sub></td><td>4-GH<sub>3</sub>OG<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 2</td>
<td> “<sup>ct</sup>3</td><td>4-ClG<sub>6</sub>H<sub>4</sub></td><td>4-CH<sub>3</sub>0G<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 0</td>
<td>-CE<sub>3</sub></td><td> °6<sup>H</sup>5</td><td>4-GH<sub>3</sub>OG<sub>6</sub>H<sub>4</sub></td><td>H</td><td> 0</td>
<td>-gf<sub>3</sub></td><td><sup>Ç</sup>6<sup>H</sup>5</td><td>3,4-diClC<sub>6</sub>H<sub>3</sub></td><td>H</td><td> 2</td>
<td>-ge<sub>3</sub></td><td>'4-FC<sub>6</sub>H<sub>4</sub></td><td>4- (GH<sub>3</sub>)<sub>2</sub>NC<sub>6</sub>H</td><td> 4<sup>H</sup></td><td> 0</td>
<td>-gf<sub>3</sub></td><td>4-EC<sub>6</sub>H<sub>4</sub></td><td>4-BrG<sub>g</sub>H<sub>4</sub></td><td>H</td><td> 0</td>
<td>-G?<sub>3</sub></td><td>4-ec<sub>6</sub>H<sub>4</sub></td><td>4-GH<sub>3</sub>GH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>Ç<sub>6</sub>H</td><td> 4<sup>H</sup></td><td> 0</td>
<td>-cf<sub>3</sub></td><td>4-FC<sub>6</sub>H<sub>4</sub></td><td>4-ch<sub>3</sub>ch<sub>2</sub>gh<sub>2</sub>gh<sub>2</sub>og<sub>&</sub></td><td>H<sub>4</sub> H</td><td> 0</td>
<td>-Ç?<sub>3</sub></td><td>4-fg<sub>6</sub>H<sub>4</sub></td><td>4- (the<sub>2</sub>H<sub>5</sub>)<sub>2</sub>uo<sub>6</sub></td><td>H<sub>4</sub> H</td><td> 0</td>
<td>-GH<sub>2</sub>GH<sub>2</sub>CH<sub>2</sub>F</td><td>4-EG<sub>6</sub>H<sub>4</sub></td><td> 4-¾</td><td>H</td><td> 0</td>
EXAMPLE 73 1-Acetyl-4,5-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole
A mixture of 1.8 g of 4,5-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole and 25 ml of acetic anhydride was
<img file="PT72087B_D0069.tif" />
heated to reflux with stirring under a nitrogen atmosphere for two days and then concentrated under vacuum. The residue was purified by chromatography on Silic AR CC-7 (eluting with hexane and then hexane / toluene) to give 400 mg of a colorless solid product. Recrystallization from ethanol / H2 O gave a m.p. analytical sample, mp 75-76Â °.
Analysis: Calculated for: θΐ9 ^ ΐ2 ^ 5 ^ θ®<sup>: G</sup>57.43; H 3.04;
N, 3.52.
Found: C, 57.05; H 3.15; N, 3.51.
<img file="PT72087B_D0070.tif" />
EXAMPLE 74 1-Methyl-4,5-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole
A dispersion of sodium hydride (0.45 g, 9 millimoles) was reacted with 30 ml DMSO under stirring nitrogen. After gas evolution had ceased, a solution of 2.13 g (6 millimoles) of 4,5'-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole in 6 ml DMSO was added dropwise at room temperature. environment. After stirring at room temperature for 15 minutes, 2.1 g (15 millimoles) of methyl iodide were added and the reaction mixture was stirred for 30 minutes. The reaction mixture was then poured into water and the product extracted with ether. Combined ethereal extracts were washed 3 times with water and, after drying, evaporated to give 2.3 g of crystals.
The above crystals combined with 700 mg of product obtained from a previous phase and purified by chromatography on Silic AR CC-7 (eluting with hexane) to give 2.4 g of product, mp 76-77 ° C.<sup>The</sup>C (ethanol / water).
Analysis: Calculated for: C19 H23 N3 O5 N, C, 58.53;
N, 3.79.
Found: C, 58.76; H, 3.48; N, 3.77 ·
<img file="PT72087B_D0071.tif" />
Example 75
1-Ethoxycarbonyl-4,5-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole
A mixture of 700 g (2 mmol) of 4,5-bis- (4-fluorophenyl) -2- (trifluoromethylthio) pyrroles and 330 mg (3 mmol) of potassium tert-butoxide was 20 mL of toluene was heated to reflux. with stirring and then cooled to room temperature under nitrogen. A solution of 700 mg (6 millimoles) of ethyl chloroformate in 15 ml of toluene was then added dropwise and the reaction mixture stirred at room temperature for several hours. The mixture was poured into aqueous sodium bicarbonate solution and the product extracted with methylene chloride. The combined organic layers were dried and concentrated to give 800 mg of a viscous oil. The oil was purified by chromatography on Silic AR 00-7 (eluted with hexane and then hexane / toluene mixtures), followed by recrystallization from ethanol / water to give 400 mg of colorless crystal product, mp 54-54.520 ° C. .
Analyze; Calculated for: 0.56.21; H, 3.30;
R, 3.28.
Found: 0, 56.46; H, 3.43; R, 3.16.
EXAMPLE 76 1-Benzoyl-4,5-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole
A mixture of 2.1 g (6 mmol) of 4,5-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole and 1.3 g (12 mmol) of potassium tert-butoxide in 60 mL of toluene was heated to reflux with stirring and then cooled to room temperature under nitrogen. A solution of 1.7 g of benzoyl chloride and 15 ml of toluene was then added and the reaction mixture was stirred overnight at room temperature. The mixture was diluted with methylene chloride, which was washed with 10% aqueous sodium bicarbonate solution, dried and evaporated. The residue was purified by 100-200 mesh Eisher silica gel chromatography (eluted with hexane and then by hexane / toluene mixtures) followed by recrystallization.
<img file="PT72087B_D0072.tif" />
Ethanol / water to give 1.8 g
mp 105.5-10020.
Analysis: Calculated for: O ^^ H ^ F ^ NOS:
N, 3.05.
Found: 0.62.83; H, of colorless crystals,
0, 62.74; H, 3.07;
3.22; N, 2.90.
Example 77
1-Benzenesulfonyl) -4,5-bis- (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole
<img file="PT72087B_D0073.tif" />
Using the procedure described in Example 75> 700 mg (2 millimoles) of 4,5-bis (4-fluorophenyl) -2- (trifluoromethylthio) pyrrole was reacted with 53C & g (3 millimoles) of benzenesulfonyl chloride. The crude reaction product was purified by 100-200 mesh Fisher silica gel chromatography (eluted with hexane and then hexane / toluene mixtures), followed by recrystallization from hexane to give 250 mg of colorless crystals, mp 133-133.5<sup>s</sup>0.
Analysis: Calculated for: C<sub>P</sub>H, Ft-NO<sub>9</sub>s<sub>9</sub>: 0, 55,75;
H, 2.85; U, 2.83.
Found: 0.55.46; H, 2.88; N, 2.98.
Table VIA illustrates other compounds that may be prepared by the processes described above.
<img file="PT72087B_D0074.tif" />
Λ-r. · '
<img file="PT72087B_D0075.tif" />
<img file="PT72087B_D0076.tif" />
<td>O</td><td>H</td><td>CM</td><td>O</td><td>O</td><td>O</td><td></td><td>CM</td><td></td><td>O</td>
<td></td><td></td><td>CM</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td>X— »</td><td></td><td></td><td></td><td></td><td></td><td></td><td>ro</td>
<td></td><td></td><td>ro</td><td></td><td></td><td></td><td></td><td></td><td></td><td>f — X</td>
<td></td><td></td><td>W</td><td></td><td></td><td></td><td>ro</td><td>CM</td><td></td><td>ro</td>
<td>ro</td><td>, CM</td><td>O</td><td></td><td></td><td>W</td><td>W</td><td>W</td><td>O.</td><td>W</td>
<td>W</td><td>w</td><td>S — t</td><td>CM</td><td></td><td>O-</td><td>O</td><td>O</td><td>CM</td><td>O</td>
<td>O</td><td>O</td><td>w</td><td>W</td><td>CM</td><td>O</td><td></td><td>O</td><td>w</td><td></td>
<td>rO</td><td>ll</td><td>CM</td><td>O</td><td>w</td><td><sub>l</sub>cm</td><td></td><td>c ~ -</td><td>O</td><td>O</td>
<td>Z — x</td><td>W</td><td>X</td><td>O</td><td>O</td><td>W</td><td></td><td>W</td><td> 0-0</td><td>o = o</td>
<td>CM</td><td>O</td><td>CM</td><td>CM</td><td>O</td><td>O</td><td></td><td>ro</td><td>O</td><td>O</td>
<td>W</td><td>CM</td><td>w</td><td>w</td><td>. ro</td><td>ro</td><td></td><td>O</td><td>CM</td><td>CM</td>
<td>O</td><td>W</td><td>O</td><td>O</td><td>W</td><td>W</td><td></td><td> 1</td><td>w</td><td>w</td>
<td></td><td>O</td><td>y ^ ·</td><td>-S.</td><td>O</td><td>O</td><td></td><td>The</td><td>O</td><td>O</td>
"there
Η>
ok
Ω ω
The rf
Et
<img file="PT72087B_D0077.tif" />
W
4Ί w ro o W
WWW
CM
W o
W o
rol WI
W
CO
O w
I d * w ° co
<td></td><td></td><td>O</td><td></td><td></td><td></td>
<td></td><td>«D-</td><td>H</td><td>«D-</td><td></td><td>«D ·</td>
<td>«D ·</td><td>w</td><td>O</td><td>W</td><td>«D-</td><td>w</td>
<td>W</td><td>co</td><td>•H</td><td>co</td><td>W</td><td>co</td>
<td>co</td><td>O</td><td>Ό)</td><td>O</td><td>co</td><td>O</td>
<td>O</td><td>H</td><td> 1</td><td>The</td><td>O</td><td>ι — 1</td>
<td>w</td><td>O</td><td>«D ~</td><td>w</td><td>W</td><td>O</td>
<td> 4-</td><td> 4-</td><td>ro</td><td> 4-</td><td> 4-</td><td>1 «D-</td>
CO
O w
4d w
CO
O ° CM
W o
ro
W
O
Go
Ρ5Ί
<td></td><td>kT * · W co O O</td><td>«D- W</td><td>W</td><td>w * co</td>
<td>w</td><td>ro</td><td>CO</td><td>CO</td><td>O</td>
<td>O</td><td>w</td><td>O</td><td>O</td><td rowspan="2">w 1</td>
<td>w</td><td>O</td><td>w</td><td>w</td>
<td> 4-</td><td>1 «D-</td><td> 4-</td><td>1 «D-</td><td>• 'd-</td>
<td colspan="4">O</td>
<td>H</td><td></td><td></td><td>O</td>
<td>•H</td><td></td><td>M ·</td><td>I — 1</td>
<td>• d</td><td>«D-</td><td>M</td><td>Ή</td>
<td>•H</td><td>w</td><td>GRANDFATHER</td><td>The</td>
<td>The</td><td>CO</td><td>O</td><td>ω</td>
<td>•H</td><td>O</td><td>H</td><td>• rl</td>
<td>Pr</td><td>W</td><td>O</td><td>-P</td>
<td> 1</td><td> 1</td><td> |</td><td> 1</td>
<td>ro</td><td>d-</td><td>tJ-</td><td>CM</td>
<td></td><td>ro</td>
<td>W</td><td>W</td>
<td>O</td><td>O</td>
<td>II</td><td>rO</td>
<td>w</td><td>^ —X</td>
<td>O</td><td>. CM</td>
<td>CM</td><td>w</td>
<td>w</td><td>O</td>
<td>O</td><td></td>
CM
The ro
W
O w<sup>w</sup> O
. ro ro ro WWW ooo ro ro wwoo i'o
cd ϋ
tf • tf
-P tf
I
-The!
H t>
«5 ra cú
Etf
Pll vo fti pfl ro ftf I rH
<img file="PT72087B_D0078.tif" />
<td colspan="2">O</td><td>CM</td><td colspan="2">H</td><td>rtf</td><td colspan="2">H</td><td>CM</td><td>O</td>
<td>1 O</td><td></td><td>1 O</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td>tf</td><td></td><td>tf</td><td></td><td></td><td>rO</td><td></td><td></td><td></td><td></td>
<td>• d</td><td></td><td>• d</td><td></td><td></td><td>The</td><td></td><td></td><td>ro</td><td></td>
<td>• tf</td><td></td><td>• tf</td><td></td><td></td><td>O</td><td></td><td></td><td>The</td><td></td>
<td>tf</td><td>O</td><td>rtf</td><td></td><td></td><td>ro</td><td></td><td></td><td>O</td><td></td>
<td>frog</td><td>H</td><td>ro</td><td></td><td></td><td>zx</td><td></td><td></td><td>CM</td><td></td>
<td>tf</td><td>•H</td><td>tf</td><td>O</td><td></td><td>CM</td><td>Ό</td><td></td><td>/ X</td><td>Oc</td>
<td>-P</td><td></td><td>-P</td><td>Ή</td><td>ro</td><td>The</td><td>CM</td><td></td><td>CM</td><td>CM</td>
<td>frog</td><td>CD</td><td>frog</td><td>• tf</td><td>The</td><td>O</td><td>The</td><td>rO</td><td>The</td><td>The</td>
<td>-P</td><td></td><td>-P</td><td>tf</td><td>O</td><td></td><td>O</td><td>The</td><td>O</td><td>O</td>
<td> 1</td><td>•H</td><td> 1</td><td>tf</td><td>O</td><td>O</td><td>O</td><td>O</td><td>X_z</td><td> |</td>
<td>CM</td><td>P)</td><td>CM</td><td>Ή</td><td>o = o</td><td> 0=0</td><td> 0=0</td><td> 0=0</td><td> 0=0</td><td>o = o</td>
ro
W
MW o W
You
O
Pm
the tn
W vo
OR
the vo
<td></td><td colspan="4">O</td><td colspan="3"></td>
<td>M ·</td><td></td><td></td><td>CM</td><td></td><td></td><td></td><td>The</td>
<td>The</td><td></td><td></td><td>/ X</td><td></td><td>M ·</td><td></td><td>grandfather</td>
<td>grandfather</td><td></td><td>• Φ</td><td>ro</td><td></td><td>The</td><td>The</td><td>O</td>
<td>O</td><td>w</td><td>The</td><td>The</td><td>The</td><td>CO</td><td>grandfather</td><td>O</td>
<td>rO</td><td>grandfather</td><td>grandfather</td><td>O</td><td>grandfather</td><td>O</td><td>O</td><td>ro</td>
<td>The</td><td>O</td><td>O</td><td>Xz</td><td>O</td><td>tf</td><td> 1—1</td><td>The</td>
<td>O</td><td>Ph</td><td>The</td><td>The</td><td>The</td><td>The</td><td>O</td><td>O</td>
<td> 1</td><td> 1</td><td> 1</td><td> 1</td><td> 1</td><td>I</td><td>I</td><td>I</td>
<td>rO</td><td>CM</td><td>'Φ</td><td>• Φ</td><td>χφ</td><td>ro</td><td>CM</td><td>CM</td>
<td></td><td>• φ The</td><td>rtf • tf</td><td>O</td><td colspan="2">The grandfather</td><td colspan="4">O iH</td>
<td>Φ</td><td>grandfather</td><td>• d</td><td>ntf</td><td>O</td><td></td><td>O</td><td>χφ</td><td>• Φ</td><td>χφ</td>
<td>The</td><td>O</td><td>tf</td><td>• tf</td><td>O</td><td>The</td><td>• tf</td><td>The</td><td>The</td><td>The</td>
<td>grandfather</td><td>rO</td><td>tf</td><td>M</td><td>ro</td><td>grandfather</td><td>Mtf</td><td>grandfather</td><td>grandfather</td><td>grandfather</td>
<td>O</td><td>The</td><td>• tf</td><td>Ό</td><td>The</td><td>O</td><td> 1</td><td>O</td><td>O</td><td>O</td>
<td>The</td><td>O</td><td>Pi</td><td> 1</td><td>O</td><td>The</td><td>• Φ</td><td>The</td><td>The</td><td>The</td>
<td> 1</td><td> 1</td><td> 1</td><td>The</td><td> 1</td><td> 1</td><td>•s</td><td> 1</td><td>I</td><td> 1</td>
<td>• φ</td><td>ro</td><td>ro</td><td> 1</td><td>• Φ-</td><td></td><td>ro</td><td>'φ</td><td>• Φ</td><td>χφ</td>
ro a
O
CM a
rO a
O
CM a
the ro
W
O
CM zx
CM a
ro a
ro a
Pm
CM
W
O
CM ro
The ro
Pm
O
CM a
O
CM a
the ro
Pm
dl
<img file="PT72087B_D0079.tif" />
ο
W}
OJ a
d • rl
-P d
oo
vol tf I
<td>O</td><td>O</td><td>CJ</td><td>tf</td><td>O</td><td>O</td><td>CJ</td><td></td><td>OJ</td><td>tf</td><td>O</td><td>OJ</td><td>O</td><td>tf</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>OJ</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>CO</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td>O</td><td></td><td></td><td></td><td></td><td> 4-</td><td>OJ</td><td></td><td>CJ</td><td></td><td></td><td></td>
<td></td><td>O</td><td>O</td><td>O</td><td></td><td>OJ</td><td>OJ</td><td>W</td><td>O</td><td></td><td>O</td><td></td><td></td><td>CVI</td>
<td></td><td>O</td><td> 4-</td><td>O</td><td></td><td>O</td><td>O</td><td>grandfather</td><td>QC</td><td></td><td>co</td><td></td><td> 1</td><td></td>
<td>O</td><td> 4-</td><td>tf</td><td> 4-</td><td></td><td>ω</td><td>co</td><td>O</td><td> 4-</td><td></td><td>ro</td><td></td><td>OJ</td><td>ro</td>
<td>O</td><td>W</td><td>GRANDFATHER</td><td>tf</td><td></td><td>jd ·</td><td> 4-</td><td>O</td><td>W</td><td></td><td></td><td>OJ</td><td>O</td><td>W</td>
<td> -4-</td><td>GRANDFATHER</td><td>O</td><td>grandfather</td><td>OJ</td><td>tf</td><td>w</td><td>OJ</td><td>grandfather</td><td></td><td>OJ</td><td>z — X</td><td>co</td><td>O</td>
<td>W</td><td>O</td><td>O</td><td>O</td><td>O</td><td>grandfather</td><td>grandfather</td><td></td><td>O</td><td>OJ</td><td>tf</td><td>ro</td><td>cn</td><td>CJ</td>
<td>grandfather</td><td>ro</td><td>ro</td><td>OJ</td><td>ω</td><td>O</td><td>O</td><td>.0J</td><td>OJ</td><td>O</td><td>O</td><td>M</td><td>tf</td><td>W</td>
<td>O</td><td>w</td><td>W</td><td>O</td><td>in</td><td>tf</td><td>OJ</td><td>M</td><td>Ό</td><td>co</td><td>-—X</td><td>O</td><td>tfj-</td><td>O</td>
<td>tf</td><td>O</td><td>O</td><td>tf</td><td>W</td><td>O</td><td>tf</td><td>O</td><td>tf</td><td>ro</td><td>ro</td><td></td><td>O</td><td></td>
<td> 1</td><td> 1</td><td> 1</td><td> 1</td><td>grandfather</td><td> 1</td><td>O</td><td></td><td> 1</td><td>W</td><td>W</td><td>tf</td><td> 1,</td><td>tf</td>
<td> 4-</td><td>ro</td><td>CJ</td><td> -4·</td><td>O</td><td> 4-</td><td>ro</td><td>ro</td><td>ro</td><td>O</td><td>O</td><td> 0=0</td><td>dl</td><td>o = co</td>
O
I c \ J o
I ro «Ί
W tf tf tf W
OJ tf o
tf<sup>1</sup> the tf
W tf tf W ro tf o
H i>
ctf
I-1 ω
tf d
EH
-4M ro
W vo o -4 · tf tf O VO tf ro
W
VO o
the ro
W
The TF
-4W you
The list tf I
M
GRANDFATHER
<td>GRANDFATHER</td><td>GRANDFATHER</td><td>grandfather</td><td>O</td><td>tf</td><td>GRANDFATHER</td><td>ro</td><td>grandfather</td><td>grandfather</td><td>O</td><td>ro</td><td>O</td><td>V £</td>
<td>O</td><td>O</td><td>O</td><td>tf</td><td rowspan="2"> 4-</td><td>O</td><td>I</td><td>O</td><td>O</td><td>d</td><td>W</td><td> 14</td><td>O</td>
<td>tf</td><td>tf</td><td>tf</td><td>O</td><td>tf</td><td>tf</td><td>tf</td><td>tf</td><td>tf</td><td>O</td><td>tf</td><td>tf</td>
<td> 1 4-</td><td>1 CJ</td><td> 4-</td><td>1 ro</td><td>* » rO</td><td> 4-</td><td> 4-</td><td> 4-</td><td>1 ro</td><td> 4-</td><td> 4-</td><td>ci.</td><td>1 ro</td>
w * o o
tf
4oj | tf I
H tf I
The tf • H
M
Ό
<td>O</td><td></td><td> 4-</td><td></td><td></td><td></td><td></td><td></td><td> 1</td><td></td><td></td><td></td>
<td>«-I</td><td></td><td>w</td><td></td><td></td><td></td><td>O</td><td></td><td>tf</td><td></td><td></td><td></td>
<td>•H</td><td></td><td>grandfather</td><td></td><td></td><td></td><td>Ή</td><td> -4</td><td>Ή</td><td></td><td></td><td> 4-</td>
<td></td><td> 4-</td><td>O</td><td> -4</td><td> 4-</td><td> 4*</td><td>•H</td><td>w</td><td>tf</td><td> 4*</td><td> 4·</td><td>M</td>
<td>•H</td><td>tf</td><td>O</td><td>tf</td><td>tf</td><td>tf</td><td>d</td><td>grandfather</td><td>• r |</td><td>M</td><td>w</td><td>grandfather</td>
<td></td><td>GRANDFATHER</td><td>ro</td><td>GRANDFATHER</td><td>grandfather</td><td>GRANDFATHER</td><td>(D</td><td>O</td><td>d</td><td>grandfather</td><td>grandfather</td><td> 0</td>
<td>•H</td><td>O</td><td>tf</td><td>O</td><td>O</td><td>O</td><td>• rl</td><td>tf</td><td>• rl</td><td>O</td><td> 0</td><td>d</td>
<td></td><td>tf</td><td>O</td><td>tf</td><td>tf</td><td>tf</td><td>•P t</td><td>O</td><td>Pl</td><td>tf</td><td>tf</td><td>tf |</td>
<td>1 ro</td><td> 1 4-</td><td> 4-</td><td> 4-</td><td> 4-</td><td> 1 4-</td><td>1 OJ</td><td> 4-</td><td>1 ΓΟ</td><td></td><td> 4-</td><td>I OJ</td>
rO rQ tf
Pm OO
O ro CVl tf t OO ro ro W tf
The cvl
W
The ro tf
O rO w
the ro tf
The ro tf
The ro tf
The tf<sup>4</sup>
O o
OJ tf o
tf<sup>1</sup> you tf tf you tf
4tf oJ tf o
ro tf
O ro w
the tí fe:
ril vol
WI
CM '(IfiTUGflí ·' ·
i.
<img file="PT72087B_D0080.tif" />
w ro o ro W o O
CM wo CM w ro o
CM
W o
ro
W
O o = oo
CM
W
O o
O
CM
W
The ts.
O o
ro t
CM
W
The ro
W o
oo
dw vo o
uncle
CM
The ω
dW you
Pm
I will go
laugh at
laughs • rl
-P laughs
O
«)
H>
laugh
H (D
Laugh
IN pTl rol
WI pd
WWW ro
CM
ΓΟ
W
WWW
<td></td><td>w</td><td>d-</td><td>O</td><td></td><td> «4-</td><td>w</td><td></td>
<td></td><td>of</td><td>w</td><td>Pm</td><td>d *</td><td>M</td><td>grandfather</td><td>d *</td>
<td>The-</td><td>W</td><td>grandfather</td><td>'Μ-</td><td>W</td><td>GRANDFATHER</td><td>O</td><td>W</td>
<td>N</td><td>VO ro</td><td>O</td><td>Ι</td><td>grandfather</td><td>O</td><td>ro</td><td>grandfather</td>
<td>RV</td><td>pw</td><td>O</td><td> 1“1</td><td>O</td><td>rH</td><td>W</td><td>O</td>
<td>Ph I</td><td>Pm | I</td><td></td><td>O</td><td>Pm</td><td>O</td><td>O</td><td>Pm</td>
<td> 1 4*</td><td>'D- d-</td><td></td><td>1 ro</td><td> 4</td><td>1 m</td><td>1 C \ J</td><td> 4</td>
dw ro
W o o
-¾ dW
VO o
fO
CM
Pm
4th
<td>w</td><td></td><td>d-</td><td>d-</td>
<td>O</td><td>d-</td><td>W</td><td>W</td>
<td></td><td>W</td><td>GRANDFATHER</td><td>grandfather</td>
<td>rn</td><td>GRANDFATHER</td><td>O</td><td>O</td>
<td>w</td><td>O</td><td>H</td><td>laugh</td>
<td>O</td><td>Pm</td><td>O</td><td>w</td>
<td>1 d-</td><td> 4</td><td>1 ro</td><td>1 CM</td>
dw vo o
O
CM w
the ro
W o
d
W o o
Pm give
CVL
W o
ro
CM ro to Pm OO 'ro w
the ro
Pm
O
CM w
The tri
O
CVl
W o
ro w
the ro
Pm
ro
Pm
<img file="PT72087B_D0081.tif" />
Dosage Forms
The antiarthritic agents and analgesic agents of the present invention may be administered to treat arthritis or relieve pain by any means that produce contact of the active agent with the sites where the acting agents are in the mammalian body. They may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They may be administered alone, but are generally administered with a chosen pharmaceutical carrier based on the preferred route of administration and customary pharmaceutical practice.
The dosage administered will, of course, vary depending upon known factors such as pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health and weight of the patient; nature and extent of symptoms, type of concurrent treatment, frequency of treatment, and intended effect. Typically, a daily dose of active ingredient may range from about 0.05 to 40 mg per kg body weight. Ordinarily, 0.1 to 20 and preferably 0.2 to 10 mg / kg per day administered in divided doses 2-4 times per day or in a slow release form is effective to achieve the desired results.
Dosage forms (compositions) suitable for internal administration contain from about 5 mg to about 500 mg of active ingredient per unit. In such pharmaceutical compositions, the active ingredient will usually be present in an amount of about 0.5-96 by weight, based on the total weight of the composition.
The active ingredient may be administered orally in solid dosage forms such as capsules, tablets and powders, or in liquid dosage forms such as elixire, syrups and suspensions and may also be administered parenterally in sterile liquid dosage forms.
Gelatin capsules contain the active ingredient and powdery carriers such as laotose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. Similar diluents may be used to make tablets. Both tablets and capsules
<img file="PT72087B_D0082.tif" />
L · ··
<img file="PT72087B_D0083.tif" />
<img file="PT72087B_D0084.tif" />
F-. .-- I<sup>:</sup>
<img file="PT72087B_D0085.tif" />
<img file="PT72087B_D0086.tif" />
they can be manufactured as slow release products to provide continuous release of the drug over a period of hours. Tablets may be sugar coated or film coated to disguise any unpleasant taste and protect the tablets from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
However, they may contain patient dyes.
liquid dosages for oral administration and flavoring to increase acceptance
In general, water, a suitable oil, physiological salt solution, aqueous dextrose (glucose) and related sugar solution and glycols such as propylene glycol or polyethylene glycol are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water-soluble salt of the active ingredient, suitable stabilizing agents, and, if necessary, buffer substances . Antioxidant agents such as sodium disulfide, sodium sulfite, asoorbic acid, either alone or in combination, are suitable stabilizing agents. Citric acid and its salts and sodium salt of EDTA are also used. In addition, parenteral solutions may contain preserving agents, such as benzalkyl chloride, methyl or propyl paraben and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, BW Martin, a standard reference text in this field.
Pharmaceutical dosage forms useful for the administration of the compounds of the present invention may be illustrated as follows:
Capsules
A large number of unit capsules are prepared by filling standard two-piece gelatin capsules, each containing 50 mg of pulverized active ingredient, 110 mg of lactose, 32 mg of talc and 8 mg of magnesium stearate.
Capsules
A blend of soybean oil active ingredient
<img file="PT72087B_D0087.tif" />
It is prepared and injected by means of a positive displacement pump into gelatin to make soft gelatin capsules containing 50 mg of the active ingredient. The capsules were washed with petroleum ether and dried.
Pills
A large number of tablets are prepared by conventional procedures so that the dosage unit contains 50 mg active ingredient, 7 mg ethyl cellulose, 0.2 mg colloidal silicon dioxide, 7 mg magnesium stearate, 11 mg of microcrystalline cellulose, 11 mg cornstarch and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
Pharmaceutical Utility
One method for detecting and comparing the antiinflammatory activity of compounds in this series and with standard drugs for which there is a good correlation with human efficacy is the rat-induced adjuvant arthritis assay.
One method for detecting and comparing the analgesic activity of compounds in this series and the activity of standard drugs for which there is a good correlation with human efficacy is the phenylquinone seizure assay.
Assay procedures employed to determine anti-inflammatory and analgesic activity are described below with the results of those included in Tables VII and VIII.
Adjuvant-induced arthritis in rats
Male Charles River lewis rats (130-150 g) are injected subcutaneously into the plantar area of the right hind paw with 0.1 ml of adjuvant (Myco bacterium butyrioum, heat-killed, Dif ··co, suspended). in mineral oil 5 mg / ml). 20 non-arthritic controls are injected with mineral oil. The animals were kept for 2 weeks to allow arthritis to develop. Paw volumes (uninjected left hind paw) are measured and the rats injected with the adjuvant are trimmed and distributed into treatment groups of 10 animals with equal disease severity. Non-arthritic controls are available.
<img file="PT72087B_D0088.tif" />
The rats are given oral doses of compound or PVA-Acacia (1% Polyvinyl Alcohol, Acacia Gum, 5% Methylparaben USP) (10 ml / kg) on that day and within 6 days. following. One day after administration of the last dose, paw volumes (injected left hind paws) are measured using a Model 7101 Ugo Basile Differential Volume Meter.
Average Paw Volume with Control Average Paw Volume of
Arthritic (ml) “Treatment Group (ml)
--- XOO
Mean Paw Volume Mean Paw Volume with Non-Arthritic Arthritic Control (ml) - (ml) $ Decreased Mean Control Paw Volume.
The dose-response regression lines of the decrease in $ are plotted on semi-logarithmic paper by visual adjustment and the DE 50% decrease from the control paw volume is determined by inspection.
Phenylquinone Seizure Test Phenylquinone Seizure Test, modified by Siegmund et al., Proc. Soc. Exp. Biol. Med. 95, 729 (1957), was employed. A 1% methylcellulose suspended test compound was orally administered to fasting white female rats (17-21 hours), 5-20 animals by double-blinded assay. Aqueous eenylquinone (0.01% phenyl-benzoquinone) was injected intraperitoneally 24 minutes using 0.20 ml per rat. Beginning 30 minutes after oral administration of the test compound, rats were observed for 10 minutes to observe the characteristic appearance of stretching or seizure syndrome that is indicative of phenylquinone pain. The effective analgesic dose for 50% of rats (ΏΕ ^ θ) was calculated by the Thompson, WR, B mean movement method.<sub>The</sub>, ct. Rev. 11, 115-145 (1947).
Ϋ ίϋ
H rd hC
Ό
Ο ο
• rd pq φ
TJ εΰ η
• rd ί>
• rd
Υ υ
O hO ο A • Η \ ra ω '0) S hO rH
π) ο «aj Ρ) Ο
Η
0)
D • Η fd
-Ρ
5 <5
Π π3 $ 1 nzf
Ο φ
Ρ hD
There
<img file="PT72087B_D0089.tif" />
<td>in</td><td>O</td><td>in</td><td>O</td><td>O</td><td>co</td><td>co</td><td>co</td><td> 00</td><td>co</td>
<td>rn</td><td>m</td><td>m</td><td>rn</td><td>m</td><td>O</td><td>O</td><td>ass</td><td>O</td><td>O</td>
<td>Ή</td><td></td><td>H</td><td>H</td><td>rd</td><td>r “4</td><td></td><td></td><td>H</td><td>H</td>
<td>Λ</td><td></td><td>Λ</td><td>Λ</td><td>THE</td><td>Λ</td><td>Λ</td><td></td><td>Λ</td><td>Λ</td>
ιη
<td>ass</td><td>c ~ -</td><td>ire</td><td>co</td><td>OJ</td><td>O</td><td>«-Í</td><td></td><td>O</td>
<td></td><td>I'm</td><td>I'm</td><td>I'm</td><td></td><td>I'm</td><td>I'm</td><td>O</td><td></td>
<td>'IA</td><td></td><td>"H</td><td>ass</td><td>VP.</td><td>ass</td><td>H</td><td>rO</td><td>CO</td>
cn
Η
<img file="PT72087B_D0090.tif" />
Ι ιη
CD m
* Ί · <
fd <ί
Ο
Η φ
Η why>
ASS
V)
CM cu m rn m cn mm rn mmm
PdPdPdPd PdPdPdPdPd Pd ooooooooo o
<td></td><td></td><td></td><td></td><td>'d-</td><td></td><td></td><td></td><td></td>
<td></td><td>H·</td><td></td><td></td><td>W</td><td></td><td></td><td>'d ·</td><td></td>
<td></td><td>w</td><td></td><td></td><td>co</td><td></td><td></td><td>w</td><td>Tl-</td>
<td></td><td>co</td><td></td><td>xl ·</td><td>O</td><td></td><td>jh-</td><td>CD</td><td>w</td>
<td></td><td>O</td><td> ,?4-</td><td>w</td><td>O</td><td>H-</td><td>W</td><td>O</td><td>co</td>
<td></td><td>O</td><td>W</td><td>co</td><td>in</td><td>w</td><td>co</td><td>O</td><td>O</td>
<td></td><td>m</td><td>co</td><td>O</td><td>W</td><td>CD</td><td>O</td><td>rr</td><td>O</td>
<td>in</td><td>M</td><td>O</td><td>rH</td><td>ass</td><td>O</td><td>rd</td><td>ω</td><td>m</td>
<td>M ·</td><td>O</td><td>Pd</td><td>O</td><td>O</td><td>Pd</td><td>O</td><td>O</td><td>W</td>
<td>co O</td><td>1 -d-</td><td> 4-</td><td> 4</td><td>1 M ·</td><td>1 •H</td><td>1 d</td><td>1 H·</td><td>O 1</td>
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>'d-</td>
ITl w
CO o
W * co
ο m
LH I'm Wo * dcu
<td></td><td>'d ·</td><td></td><td>H·</td><td></td><td></td><td>Ή-</td>
<td>M-</td><td>w</td><td>M-</td><td>W</td><td>-d ·</td><td>H-</td><td>w</td>
<td>W</td><td>co</td><td>w</td><td>co</td><td>W</td><td>w</td><td>co</td>
<td>co</td><td>O</td><td>co</td><td>O</td><td>co</td><td>co</td><td>O</td>
<td>O</td><td>H</td><td>O</td><td>rd</td><td>O</td><td>O</td><td>H</td>
<td>Why t</td><td>O</td><td>Pd</td><td>O</td><td>Pd</td><td>Pd</td><td>O</td>
<td> 1</td><td> 4-</td><td> 4-</td><td> 1</td><td>1 «D-</td><td> 4-</td><td> 4-</td>
CO
O
Pd
I * drn in co co
rd o
will
CJ ra d
d • rrt
-J.-1 rt o
ϋ
I
H
H>
IN
<img file="PT72087B_D0091.tif" />
oo
• rrt ra '(D bD rH ra o
LfA why
<td>CO</td><td>OJ THE</td><td> 00</td><td>CO</td><td>CO</td><td>O</td><td> 00</td><td> 00</td><td>CO</td><td>co</td><td> 00</td>
<td>O</td><td>\O</td><td>O</td><td>O</td><td>O</td><td>m</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td>
<td>rt</td><td>rH</td><td>r — 1</td><td>rH</td><td> 1—1</td><td>rH</td><td>"H</td><td>• rt</td><td>rrt</td><td>rrt</td><td>rrt</td>
Co rΛΛΛΛΑΛΛΛΛ ro co rrt ra +<sup>9</sup> • ri rt + = rt <t!
ra * d ra o
• rt «1
Ό • rt
• rt
The ra • d • rt>
• rt + = o
«5 ra + =
HO
HO a
the lily
N • n Q • d <l {rt I «Ί rt rt rt rt o
H θ 'ra
W
PI
Γ-
<td></td><td></td><td>CJ</td><td>LfA</td><td>O</td><td>O</td><td></td><td>OA</td><td>CJ</td><td></td><td></td><td></td><td></td>
<td>IT \</td><td>Lf \</td><td></td><td>•THE</td><td>•THE</td><td>•THE</td><td>O</td><td></td><td></td><td>O</td><td>LPi</td><td>d-</td><td>m</td>
<td>CM</td><td>OJ</td><td>TS.</td><td>CD</td><td>rt</td><td>LfA</td><td>rrt</td><td></td><td></td><td>CJ</td><td>OJ</td><td>rO</td><td>CM</td>
<td></td><td></td><td>ro</td><td></td><td></td><td></td><td></td><td>OA</td><td>OA</td><td></td><td></td><td></td><td></td>
<td></td><td></td><td>ro</td><td></td><td></td><td></td><td></td><td>(O</td><td>rH</td><td></td><td></td><td></td><td></td>
η
Pm
O
LfA w
CD
The rt w
CD
O
Pm
4th ro ro
Pm Pm Pm OOO a
with the
ro
IU
O
4 • Hw
CD
O
ΓΟ w
O
4CJ rrt cj
Pm
OJ ro
CJ o
ro
OW Cd O ro ro ro ro aaww
OOOO ro
co
<td></td><td>O</td><td></td><td>The</td><td></td><td></td><td></td><td></td><td></td><td>The</td><td>The</td>
<td></td><td>H</td><td></td><td>CD</td><td>rt</td><td>rt</td><td></td><td></td><td>• rt</td><td>CD</td><td>CD</td>
<td>rt</td><td>O</td><td>rt-</td><td>O</td><td>The</td><td>The</td><td>rt</td><td>rt</td><td>The</td><td>O</td><td>O</td>
<td>W</td><td>• rl</td><td>The</td><td>O</td><td>CD</td><td>CD</td><td>The</td><td>The</td><td>CD</td><td>O</td><td>O</td>
<td>co</td><td></td><td>CD</td><td>rO</td><td>O</td><td>O</td><td>co</td><td>CD</td><td>O</td><td>ro</td><td>ro</td>
<td>O</td><td> 1</td><td>O</td><td>The</td><td>rrt</td><td>rt</td><td>O</td><td>O</td><td>rrt</td><td>The</td><td>The</td>
<td>Pm</td><td> 4-</td><td>Pm</td><td>O</td><td>ϋ</td><td>O</td><td>Pm</td><td>Pm</td><td>O</td><td>O</td><td>O</td>
<td>1 <O</td><td>•THE ro</td><td>1 rt</td><td>1 rt</td><td> 4-</td><td> 4-</td><td> 4-</td><td> 4-</td><td> 4-</td><td>1 rt</td><td> 4-</td>
<td></td><td></td><td></td><td>rt</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td>The</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td></td><td>CD</td><td>rt</td><td>rt</td><td></td><td>rt</td><td></td><td></td><td>rt</td>
<td>rt</td><td></td><td>rt</td><td>O</td><td>The</td><td>The</td><td>rt</td><td>The</td><td>Ή-</td><td>rt</td><td>The</td>
<td>The</td><td></td><td>The</td><td>O</td><td>co</td><td>CO</td><td>W</td><td>CD</td><td>The</td><td>The</td><td>CD</td>
<td>CD</td><td></td><td>CD</td><td>rO</td><td>O</td><td>O</td><td>CD</td><td>O</td><td>CD</td><td>CD</td><td>O</td>
<td>O</td><td>LfA</td><td>O</td><td>The</td><td>rrt</td><td>rrt</td><td>O</td><td>rrt</td><td>O</td><td>O</td><td>rrt</td>
<td>Pm</td><td>The</td><td>Pm</td><td>O</td><td>O</td><td>O</td><td>Pm</td><td>O</td><td>Pm</td><td>Pm</td><td>O</td>
<td>1 rO</td><td>CD O</td><td>1 rt</td><td>1 rt</td><td>1 rt</td><td> 4</td><td> 4-</td><td> 4-</td><td> 4-</td><td>1 rt</td><td>1 rt</td>
rO rrt
CO
LfA CD rO (O
The rt
H rt ro rt rt rt
LfA CD rt rt 'tftf
CO rO ο
I will
cti ϋ
laughs
-Ρ laugh
Ο
Ο
Η
H>
CUM
• Η
Η γΗ
Ο • Η
FQ (D
TJ d
•> ί>
• Η
-Ρ
Ο
-d
Ο Μ τ4 Λί • Η
W ω XD &
Π}
Ω ω
+<sup>3</sup> • i ri • Ρ ri d
d ω
• ρ
Ι ιη
Η) η
£ · Γ3 τ3
-d ο
ιη why
Ο οο Ο Η Η
Ι ι ιη ιη η Η ο
Ο οο νο Ι> Η
<td>ο</td><td></td><td></td><td></td><td></td><td></td>
<td>ο</td><td>ιη</td><td></td><td>ιη</td><td>ιη</td><td></td>
<td>CVI</td><td>• Φ</td><td></td><td>CV1</td><td><Μ</td><td>σι</td>
<td> \</td><td> \</td><td></td><td> \</td><td></td><td></td>
<td>th</td><td>Ί &.</td><td>Ο</td><td></td><td></td><td></td>
<td>νο</td><td>CJ</td><td>m</td><td>νο</td><td>Η</td><td>νο</td>
<td>Φ</td><td>CV1</td><td></td><td>φ</td><td>ΓΟ</td><td>ΓΟ</td>
<td></td><td></td><td></td><td></td><td></td><td>Λ — ζ</td>
ρΤΙ γΟ
Ο ο
γΟ
Μ
Ο
CVJ γΟ
W ο
ΓΟ
Ρη
Ο
ΟΊ
Laughs
-aJ φ
to ο
Tr ιη ιη trj
Μ Κ ο
VO VO |
Ο Ο 'Φ ιη
W ο ο
laughs **
Ο
Ρμ θ 'α>
Μ why
<img file="PT72087B_D0092.tif" />
<td>ιη</td><td>ιη ο</td><td>tn</td><td>Ο</td>
<td>m</td><td>ΓΟ ΓΟ</td><td>m</td><td>m</td>
<td>Η</td><td>J fJ</td><td>Η</td><td>rd</td>
<td>Λ</td><td>Ν ν</td><td>Λ</td><td>Λ</td>
<td>Ο</td><td></td><td>ο</td><td>Ç-</td><td>ο</td>
<td>Η</td><td><η η</td><td>Η</td><td>Η</td><td>CJ</td>
<Μ Cvl γΟ
Ρί
Ο γΟ ΓΟ
Aί a Ο ο (Μ & Γ<sup>1</sup>
Ο γΟ
W ο
CV1
CVL
CV1
ΓΟ
ΡΗ
Ο
ΓΟ ΓΟ Ρμ Ρί Ο ο
ΓΟ
Ρί
Ο
ΓΟ
Ρη
Ο
Ν νο ο
<td>• Μ *</td><td>«Vj-</td><td>Φ</td><td></td><td></td>
<td>Μ</td><td>W</td><td>Μ</td><td></td><td></td>
<td>νο</td><td>νο</td><td>νο</td><td></td><td></td>
<td>Ο</td><td>ο</td><td>ο</td><td>Φ</td><td>φ</td>
<td>ο</td><td>ο</td><td>ο</td><td>Η</td><td>The</td>
<td>ΓΟ</td><td>ΓΟ</td><td>ΓΟ</td><td>νο</td><td>RV</td>
<td>W</td><td>W</td><td>W</td><td>ο</td><td>ο</td>
<td>ο</td><td>ο</td><td>ο</td><td>Ρμ</td><td>Ρμ</td>
<td>Λ</td><td>Λ</td><td> 4-</td><td> 4-</td><td>I φ</td>
ο ο
1-4
Ο
Ν νο ο
Η
Ο
Λ 4Μ ·
W ο ο
ο ιη <sup>Μ</sup>.
<Μ
Ο
4'φ
W
<td></td><td>Φ</td><td></td><td></td><td>W</td><td>W</td><td>W</td><td></td><td></td><td></td><td></td><td></td>
<td><sub>L</sub>φ</td><td>Μ</td><td></td><td></td><td>νο</td><td>νο</td><td>νο</td><td></td><td></td><td>φ ·</td><td>• φ</td><td></td>
<td>The</td><td>grandfather</td><td></td><td></td><td>ο</td><td>ο</td><td>ο</td><td>φ</td><td>φ</td><td>The</td><td>Μ</td><td rowspan="2">The</td>
<td>grandfather</td><td>Ο</td><td></td><td></td><td>ο</td><td>ο</td><td>ο</td><td>Μ</td><td>The</td><td>νο</td><td>νο</td>
<td>ο</td><td>ro</td><td></td><td></td><td>γΟ</td><td>ΓΟ</td><td>γΟ</td><td>νο</td><td>νο</td><td>ο</td><td>Ο</td><td>Μ</td>
<td>Η</td><td>Μ</td><td>ιη</td><td>ιη</td><td>W</td><td>The</td><td>Μ</td><td>ο</td><td>ο</td><td>Η</td><td>ι-1</td><td>Ο</td>
<td>ϋ</td><td>ο</td><td>W</td><td>W</td><td>ο</td><td>ο</td><td>ο</td><td>Ρμ</td><td>Ρμ</td><td>Ο</td><td>Ο</td><td>Ρμ</td>
<td>1 'd-</td><td> 4-</td><td>νο ο</td><td>νο ϋ</td><td> 4-</td><td> 4-</td><td> 4-</td><td> 4-</td><td>Λ</td><td> 4-</td><td> 4</td><td> 4-</td>
φ σ>
Φ
C ιη cvl ΓΟ ιη ιη ιη νο ιη ιη tιη οο ιη σ \ ιη
C νο c
Φ • φ ιη. ··: · '··. *. j
<img file="PT72087B_D0093.tif" />
:: μ is
} Ϊσ} ο
σ5 d
<td>•H -P</td><td>rô</td>
<td>d</td><td>O</td>
<td>O</td><td>•H</td>
<td>O</td><td>Ό</td>
<td> 1</td><td>r — 1 O</td>
<td>H</td><td>♦ H</td>
<td>H ></td><td>PQ <D Kj d</td>
<td>CD</td><td>•H</td>
<td>rd</td><td>!> •H</td>
<td>O</td><td>•H O</td>
<td>powder</td><td></td>
CD
Ed
<td>O</td><td>bD</td>
<td>O</td><td>Λ1</td>
<td>Ή</td><td></td>
<td>m</td><td>bfl</td>
<td></td><td>^ a</td>
<td>good rd</td><td></td>
<td>CD</td><td>O</td>
<td>d</td><td>in</td>
<td><d</td><td>CD no</td>
Γ — 1 (ϋ
-Ρ • Η fd • ρ
Ρ cd rd ω
-Ρ bO
Ί μ
a • ΓΊ)
-d ο
ιη fd
I fi I
Cd d
<4 th
H
CD
M
Id
<img file="PT72087B_D0094.tif" />
<td>O</td><td> 00</td><td> 00</td><td>co</td><td>OO</td><td>m oo co</td><td>00 oo</td>
<td>ro</td><td>O</td><td>O</td><td>O</td><td>O</td><td>rO ro H</td><td>rO</td>
<td>r — í</td><td>H</td><td>rd</td><td>rd</td><td>H</td><td>iH</td><td>rd</td>
<td>Λ</td><td>Λ</td><td>Λ</td><td>Λ</td><td>Λ</td><td>Λ</td><td>Λ</td>
<td colspan="2"></td><td>Fifteenth LT »</td><td colspan="3"></td><td colspan="3">x ** x 0-</td><td colspan="2">x * \ 0 “</td>
<td>σ \</td><td>in</td><td></td><td>t></td><td>Ç-</td><td></td><td></td><td>CM</td><td></td><td>CM</td><td></td>
<td></td><td></td><td></td><td>CM</td><td>CM</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>iH</td><td></td><td rowspan="2"></td><td rowspan="2"></td><td></td><td>O</td><td> -6¾.</td><td>rO</td><td>Έ, <</td><td>O</td>
<td>xf ·</td><td></td><td>xh</td><td>OJ</td><td>tn</td><td>xl ·</td><td>H</td><td>ro</td><td>cn</td>
<td>I — 1</td><td></td><td>co</td><td>tn</td><td>ro</td><td></td><td></td><td>ro</td><td></td><td>CM</td><td></td>
<td></td><td></td><td></td><td>CKI</td><td>CKI</td><td></td><td></td><td> ></td><td></td><td></td><td></td>
<td>rd</td><td>CM</td><td>CM</td><td>CM</td><td>CM</td><td>CM</td><td>CM</td><td>CM</td>
<td></td><td></td><td></td><td></td><td>CM</td><td></td><td></td><td></td>
<td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>W</td><td>ro</td><td>ro</td><td></td>
<td>fd</td><td>W</td><td>W</td><td>all</td><td>O</td><td>all</td><td>id</td><td>all</td>
<td>O</td><td>O</td><td>O</td><td>O</td><td>rO</td><td>O</td><td>O</td><td>O</td>
<td></td><td></td><td></td><td></td><td>W</td><td></td><td></td><td></td>
<td></td><td></td><td></td><td></td><td>O</td><td></td><td></td><td></td>
<td></td><td></td><td> +</td><td></td><td></td><td></td><td></td><td></td>
<td>M</td><td></td><td>w</td><td></td><td></td><td></td><td></td><td> <-</td>
<td>Knockout</td><td></td><td>ko ·</td><td></td><td></td><td></td><td></td><td>id</td>
<td>O</td><td> ·+</td><td>O</td><td></td><td> ·+</td><td></td><td>saw-</td><td>Knockout</td>
<td>O</td><td>W</td><td>O</td><td>V</td><td>id</td><td>-Φ</td><td>W</td><td>O</td>
<td>m</td><td>Knockout</td><td>m</td><td>id</td><td>Knockout</td><td>all</td><td>Knockout</td><td>O</td>
<td>id</td><td>O</td><td>id</td><td>Knockout</td><td>O '</td><td>Knockout</td><td>O</td><td>ro</td>
<td>CM</td><td>rd</td><td>CM</td><td>O</td><td>rd</td><td>O</td><td>rd</td><td>fd</td>
<td>O</td><td>O</td><td>O</td><td>Pd</td><td>O</td><td>Jd</td><td>O</td><td>O</td>
<td> 4-</td><td> 1 +</td><td> 4-</td><td>1 V</td><td> 1</td><td> 4-</td><td> 4-</td><td> 4-</td>
CM
W 'Φ
W
ΚΩ
Ο
Ο <Ό
W ϋ
(Μ CM rO
4th
W ο ο m
Μ
Ο ο
• V
Knockout
ro
O
I d-
<td>• d-</td><td>xt The</td><td>XI</td><td>xh</td><td>v id</td><td>all</td><td>V</td><td>• v</td><td>v- all</td><td>v w</td><td>xf · The Knockout</td>
<td>all</td><td>Knockout</td><td>The</td><td>all</td><td>Knockout</td><td>Knockout</td><td>id</td><td>all</td><td>Knockout</td><td>Knockout</td><td>O</td>
<td>ko</td><td>O</td><td>Knockout</td><td>ko</td><td>O</td><td>O</td><td>ko</td><td>ko</td><td>O</td><td>O</td><td>ro</td>
<td>ϋ</td><td>H</td><td>O</td><td>O</td><td>rd</td><td>rd</td><td>O</td><td>O</td><td>rd</td><td>rd</td><td>The</td>
<td>fd</td><td>O</td><td>why</td><td>Fd</td><td>O</td><td>O</td><td>Pd</td><td rowspan="2">fd 4-</td><td>O</td><td>O</td><td>α</td>
<td> 4-</td><td> 1</td><td> 1</td><td> 4-</td><td> 4-</td><td>1 v</td><td> 4-</td><td> 4-</td><td>1 v</td><td>í XI</td>
H CM ko ko m d- m ko ko ko ko ko cn <-d cki ko c— ir in parentheses represent the percentage of paw volume reduction with the dose ra ω
The cd rd
QC
O •
cd rd cd o
• rd r- oo ko ko
<td>H</td><td></td>
<td>H</td><td>CD</td>
<td>H</td><td>O</td>
<td> !></td><td>•H hL Ό •H</td>
<td>CD</td><td>O •H</td>
<td>rd</td><td>fri</td>
<td>Φ</td><td>Φ Tf</td>
<td></td><td>CD Tf</td>
<td>CD</td><td>•H t></td>
<td>EH</td><td>•H</td>
+<sup>3</sup> ο
<4
Ή
<img file="PT72087B_D0095.tif" />
laughs = 4
<img file="PT72087B_D0096.tif" />
Φ +<sup>3</sup> • laughs
-Ρ laughs <4 <d
τ)
Φ
-ρ
Èi • ro * d
Ο
Lf \
<td>-Φ</td><td>O</td><td>H * »</td><td>O</td>
<td> ·»</td><td>O</td><td>rH</td><td>«T</td>
<td>H</td><td>H</td><td></td><td></td>
<td colspan="4">O</td>
<td>grandfather</td><td>cn</td><td>cn</td><td>in</td>
<td></td><td></td><td>»V</td><td></td>
<td>grandfather</td><td>t- no</td><td>H</td><td>ç-</td>
<td>ώ ° Ι</td><td>w</td><td>W</td><td>W ° O</td><td>w ° O O X _ >> O</td><td>in W grandfather O z— \ O VX O</td><td>LO M grandfather O CVI O QC</td><td>ιο w, CVL O O O O</td><td>tri</td>
<td>pTI</td><td>w</td><td>tri</td><td>tri</td><td>w</td><td>W</td><td>w</td><td>w</td><td>ίπΓ O</td>
<td>ρ! 1</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td>
<td></td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td>
<td>Η I</td><td>Pm</td><td>Pm</td><td>Pm</td><td>Pm</td><td>Pm</td><td>Pm</td><td>Pm</td><td>Pm</td>
<td>I'm 1</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td>
<td colspan="9">O</td>
<td></td><td>"H</td><td>O</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td>•H</td><td>rd</td><td></td><td></td><td></td><td></td><td></td><td></td>
<td></td><td></td><td>• rd</td><td></td><td>Φ</td><td>M-</td><td>«Φ</td><td></td><td></td>
<td></td><td>•H</td><td>laugh</td><td>w</td><td>tri</td><td>w</td><td>w</td><td>w</td><td></td>
<td></td><td></td><td>φ</td><td>grandfather</td><td>grandfather</td><td>grandfather</td><td>grandfather</td><td>grandfather</td><td></td>
<td></td><td>•H</td><td>• id</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>LO</td>
<td>“I</td><td>P</td><td> +»</td><td>Pd</td><td>Pm</td><td>Pm</td><td>Pm</td><td>Pm</td><td>w</td>
<td>laugh <4</td><td>1 rO</td><td>1 CM</td><td>1 Φ</td><td> 4-</td><td> 4-</td><td> 4-</td><td>1 * φ</td><td>grandfather O</td>
w * yo
ο
W Φ tri W ri <4
-Φ
W. . . .
ro vo vo να LO ao OO
W Ο Pd v o
Pm Pm
4- 4- 4- 4tri<sup>1</sup>
Φ
Wo yo oo
Pm
I
-Φ
Pd
4m
W vo
Ο ο
Θ θ '
Φ
Μ
) C- οο ι—) rd dro ro ο- mc— c— c— t— c—
LTV t — I ο
irf
Hi rf d
fl
Ή
-P fl
O
The rf
♦ rl ttf
Ό
H o
• rd ffl
R • d rf
Ά • rl i>
• rl
P
O o
o • rl m
\ <D
AO rd rf <0
-P • rl fl dd fl
Tj (D
-P £
• ro
Ά
THE
O
IO
O
LO
Θ
O
M2>
<img file="PT72087B_D0097.tif" />
<td>CO</td><td>oj co</td><td> 00</td><td>co</td><td>io</td><td> 00</td><td> 00</td><td> 00</td><td>io</td><td>co</td><td>00 IO</td><td> 00</td>
<td>O</td><td>CJ o</td><td>O</td><td>O</td><td>rO</td><td>O</td><td>O</td><td>O</td><td>ro</td><td>O</td><td>The ro</td><td>ι 2</td>
<td>rd</td><td>rd</td><td>rd</td><td>rd</td><td>rd</td><td>rd</td><td>rd</td><td>H</td><td>rd</td><td>rd</td><td>rd H</td><td>rd</td>
<td>Zx</td><td>zx</td><td>Zx</td><td>Zx</td><td>zx</td><td>Zx</td><td>ZX</td><td>ZX</td><td>ZX</td><td>Z \</td><td>ZXZS</td><td>ZX</td>
<td>go\</td><td></td><td></td><td></td><td>ç-</td><td></td><td></td><td></td><td></td><td>fl *</td><td>in</td><td></td><td></td><td></td>
<td></td><td>CJ</td><td>in</td><td>oo</td><td>CJ</td><td></td><td></td><td>frog</td><td></td><td>O</td><td> <-4</td><td>frog</td><td>CJ</td><td>lo</td>
<td></td><td></td><td>r »</td><td> ·*</td><td></td><td>O</td><td>lo</td><td> ·*</td><td></td><td> »»</td><td> ·»</td><td> —*</td><td>The</td><td> ·*</td>
<td></td><td></td><td>m</td><td> 00</td><td></td><td> «—1</td><td>CJ</td><td>O</td><td>CM</td><td>O</td><td>The CM</td><td>O</td><td>CJ</td><td>frog</td>
<td>σ></td><td>fl-</td><td></td><td></td><td></td><td></td><td></td><td></td><td>s</td><td></td><td></td><td></td><td></td><td></td>
<td>CM</td><td>fl-</td><td></td><td></td><td>CJ</td><td></td><td></td><td></td><td>ç</td><td></td><td></td><td></td><td></td><td></td>
inflatableWWtóWiUWWWWWWWW
CM w
o ro ro ro oJ WWWW oooo ro W o
<td>fl- I pq 1</td><td>M</td><td>W</td><td>M</td><td>W</td><td>W</td><td>W</td><td>W</td><td>W</td><td>W</td><td>W</td>
<td>fl 1</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td>
<td></td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td><td>ro</td>
<td>h I</td><td>fl)</td><td>fl)</td><td>fl)</td><td>fl)</td><td>Al</td><td>There</td><td>There</td><td>Al</td><td>There</td><td>Al</td>
<td>why 1</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td><td>O</td>
<td></td><td></td><td>fl-</td><td></td><td>THE·</td><td></td><td></td><td></td><td>fl-</td><td></td><td>O</td>
<td></td><td></td><td>W</td><td></td><td>W</td><td></td><td></td><td></td><td>w</td><td>O</td><td>rd</td>
<td></td><td></td><td>frog</td><td>fl *</td><td>frog</td><td></td><td>fl-</td><td>fl-</td><td>frog</td><td>rd</td><td>• rd</td>
<td></td><td>fl *</td><td>O</td><td>w</td><td>O</td><td>fl-</td><td>W</td><td>W</td><td>O</td><td>• rl</td><td></td>
<td></td><td>W</td><td>O</td><td>frog</td><td></td><td>W</td><td>frog</td><td>frog</td><td>co</td><td>fl</td><td>• rl</td>
<td></td><td>frog</td><td>co</td><td>O</td><td>CJ</td><td>frog</td><td>O</td><td>O</td><td>ro</td><td><D</td><td>fl</td>
<td></td><td>O</td><td>W</td><td>fl</td><td>r \</td><td>O</td><td>rd</td><td>rd</td><td>W</td><td>• r |</td><td>• fl</td>
<td>“I</td><td>why</td><td>O</td><td>why</td><td>ro</td><td>why</td><td>O</td><td>O</td><td>O</td><td>-P</td><td>P)</td>
<td>H</td><td> 1</td><td> 1</td><td> 1</td><td>W</td><td> 1</td><td> 1</td><td> 1</td><td> 1</td><td> |</td><td> 1</td>
<td>«Ί 1</td><td>CJ</td><td>fl-</td><td>fl-</td><td>O</td><td>fl-</td><td>fl-</td><td>ro</td><td>fl-</td><td>CJ</td><td>ro</td>
ro ro ro ro rO fl fl fl fl OOOOO fltd
VO ** 4 o W cj flourish W fl-o / * ra ra W o p4 mo ra m WH o WP
OO Pq O Al
4-4 4 4-4 fl <1
I fl-
<td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan="2">fl- UI frog</td><td></td>
<td></td><td></td><td></td><td></td><td></td><td></td><td>fl-</td><td></td><td></td><td></td><td></td><td>α-</td><td></td><td></td>
<td>fl-</td><td></td><td>fl ·</td><td>THE*</td><td></td><td></td><td>W</td><td>fl-</td><td>THE-</td><td>fl *</td><td>α ·</td><td>w</td><td colspan="2">TO</td><td>THE*</td>
<td>The</td><td></td><td>w</td><td>w</td><td></td><td></td><td>frog</td><td>W</td><td>w</td><td>Ud</td><td>ω</td><td>frog</td><td>ω</td><td>O</td><td>w</td>
<td>frog</td><td></td><td>frog</td><td>frog</td><td></td><td></td><td>O</td><td>frog</td><td>frog</td><td>frog</td><td>frog</td><td>O</td><td>frog</td><td>ro</td><td>frog</td>
<td>O</td><td>LO</td><td>O</td><td>O</td><td>io</td><td>LO</td><td>rd</td><td>O</td><td>O</td><td>O</td><td>O</td><td>rd</td><td>O</td><td>W</td><td>O</td>
<td>fl)</td><td>W</td><td>There</td><td>fl)</td><td>W</td><td>M.</td><td>O</td><td>fl)</td><td>fl)</td><td>fl)</td><td>fli</td><td>O</td><td>fl)</td><td>O</td><td>fli</td>
<td>1 CJ</td><td>frog O</td><td>1 fl-</td><td> 4-</td><td>frog O</td><td>frog O</td><td>1 ro</td><td> 4-</td><td>1 fl-</td><td> 4-</td><td> 4-</td><td>1 fl-</td><td> 4-</td><td> 4-</td><td> 4-</td>
O
There is<sup>1</sup> <D why
ΟΛ - | O
OJ rd
OJ
CJ
OJ
ΓΟ
OJ flOJ lo
OJ oCJ
CO
OJ cn oh cj ro CJ ro ro ro ro
OJ
4σ
<img file="PT72087B_D0098.tif" />
Essentially consisting of is meant to have its usual meaning: namely, that all specified materials and conditions are very important in the practice of the invention but that unspecified materials and conditions are not excluded provided that they do not adversely affect the benefits. of the invention so that they cannot be realized.
Contents157
98 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92 Sheet 93 Sheet 94 Sheet 95 Sheet 96 Sheet 97 Sheet 98
136 members in 23 offices
Priority claims3
| Document | Office | Kind | Date |
|---|---|---|---|
| 12250180 | United States of America | A | |
| 122501 | – | – | – |
| US19800122501 | – | – | – |
Members136
| Document | Office | Kind | |
|---|---|---|---|
| PT69336A | Portugal | A | |
| IL56856A0 | Israel | A0 | |
| DK75779A | Denmark | A | |
| FI790852A | Finland | A | |
| FI790852A7 | Finland | A7 | |
| NO790821L | Norway | L | |
| AU4504079A | Australia | A | |
| JPS54141766A | Japan | A | |
| EP0005156A1 | European Patent Office (EPO) | A1 | |
| ES478556A1 | Spain | A1 | |
| ZA791150B | South Africa | B | |
| ES484196A1 | Spain | A1 | |
| PT72087A | Portugal | A | |
| NZ189881A | New Zealand | A | |
| GR66513B | Greece | B | |
| US4267184A | United States of America | A | |
| PH14378A | Philippines | A | |
| DK448480A | Denmark | A | |
| FI804028L | Finland | L | |
| NO810547L | Norway | L | |
| AU6403280A | Australia | A | |
| EP0034798A2 | European Patent Office (EPO) | A2 | |
| EP0034798A3 | European Patent Office (EPO) | A3 | |
| PT72087BThis record | Portugal | B | |
| AR224276A1 | Argentina | A1 | |
| JPS56150060A | Japan | A | |
| AR225739A1 | Argentina | A1 | |
| CA1126275A | Canada | A | |
| ZA808109B | South Africa | B | |
| EP0005156B1 | European Patent Office (EPO) | B1 | |
| IL56856A | Israel | A | |
| DE2963707D1 | Germany | D1 | |
| ES499559A0 | Spain | A0 | |
| ES8302652A2 | Spain | A2 | |
| AU527243B2 | Australia | B2 | |
| HU180223B | Hungary | B | |
| SU1005657A3 | Soviet Union (until 1991) | A3 | |
| GR70770B | Greece | B | |
| CA1144550A | Canada | A | |
| YU58979A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| ATA73981A | Austria | A | |
| YU279080A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| MX5685E | Mexico | E | |
| IL61768A | Israel | A | |
| AT374796B | Austria | B | |
| NZ196297A | New Zealand | A | |
| PH17299A | Philippines | A | |
| AU540613B2 | Australia | B2 | |
| EP0034798B1 | European Patent Office (EPO) | B1 | |
| SU1160934A3 | Soviet Union (until 1991) | A3 | |
| DE3170571D1 | Germany | D1 | |
| JPH0250902B2 | Japan | B2 | |
| US2001039369A1 | United States of America | A1 | |
| CA2425232A1 | Canada | A1 | |
| WO0231372A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU2941201A | Australia | A | |
| CA2425584A1 | Canada | A1 | |
| WO0241484A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU3923002A | Australia | A | |
| US2002082173A1 | United States of America | A1 | |
| US6416215B1 | United States of America | B1 | |
| US2002145940A1 | United States of America | A1 | |
| WO0241484A3 | World Intellectual Property Organization (WIPO) | A3 | |
| CA2462309A1 | Canada | A1 | |
| WO03028869A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2002362448A1 | Australia | A1 | |
| EP1332299A1 | European Patent Office (EPO) | A1 | |
| EP1336243A2 | European Patent Office (EPO) | A2 | |
| IL155267A0 | Israel | A0 | |
| IL155267D0 | Israel | D0 | |
| IL155268A0 | Israel | A0 | |
| IL155268D0 | Israel | D0 | |
| US2004047232A1 | United States of America | A1 | |
| JP2004511902A | Japan | A | |
| US6758593B1 | United States of America | B1 | |
| IL161280A0 | Israel | A0 | |
| US2004218468A1 | United States of America | A1 | |
| JP2004534374A | Japan | A | |
| US6837613B2 | United States of America | B2 | |
| US2005002274A1 | United States of America | A1 | |
| WO03028869A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US6899454B2 | United States of America | B2 | |
| EP1534412A2 | European Patent Office (EPO) | A2 | |
| US2005117449A1 | United States of America | A1 | |
| JP2005523140A | Japan | A | |
| US2005201201A1 | United States of America | A1 | |
| US6965288B2 | United States of America | B2 | |
| EP1618905A2 | European Patent Office (EPO) | A2 | |
| US2006092761A1 | United States of America | A1 | |
| EP1534412A4 | European Patent Office (EPO) | A4 | |
| WO2006063087A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US7086778B2 | United States of America | B2 | |
| WO2006063087A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2006063087B1 | World Intellectual Property Organization (WIPO) | B1 | |
| US2007030759A1 | United States of America | A1 | |
| EP1618905A3 | European Patent Office (EPO) | A3 | |
| IL155267A | Israel | A | |
| US7267479B2 | United States of America | B2 | |
| US2007263484A1 | United States of America | A1 | |
| IL161280A | Israel | A |
Numbers
- Publication, DOCDB
- 72087
- Publication, EPODOC
- PT72087
- Application
- 72087
- Application, DOCDB
- 7208780
- Application, EPODOC
- PT19800072087
Titles
- English
- PROCESS FOR THE PREPARATION OF ANTIINFLAMMATORY 4,5-DIARYL-2-(SUBSTITUTED-THIO)PYRROLES AND OF THEIR CORRESPONDING SULFOXIDES AND SULFONES
Classification
- CPC, 7
- C07C251/72
- C07D207/323
- C07D207/333
- C07D207/34
- C07D207/36
- Y10S514/825
- A61P29/00
- IPC, 10
- C07D207 34
- A61K31 40
- A61P29 00
- C07D207 12
- C07D207 32
- C07D207 323
- C07D207 333
- C07D207 36
- C07D401 04
- C07D409 04
